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Chapter 1 
General introduction 
1.1 History 
The first experiments showing the presence and function of gonadotrophs 
hormones were performed simultaneously by Zondek and Aschheim (1927) and 
Smith and Engle (1927). They transplanted anterior-pituitary tissue into immatu-
re mice and rats and could induce precocious sexual maturity and superovula-
tion. They demonstrated that the gonadotrophs hormone produced by the 
anterior pituitary was the primary hormone, stimulating the ovary, which in turn 
produced a secondary hormone (Ovarialhormon or folliculin). This secondary 
hormone exerted a stimulatory effect on uterus and vagina. Cole and Hart 
reported in 1930 that serum from pregnant mares could induce sexual maturity 
in immature rats. Since then, preparations obtained from animal pituitaries and 
pregnant mare serum gonadotrophins (PMSG) were used to induce ovulation in 
amenorrhoeic women. From the 1930s onwards human chorionic gonadotrophin 
(hCG), a preparation derived from urine of pregnant women, was applied in 
clinical practice to induce ovulation after spontaneous follicular development. 
Hamblen et al. (1945) demonstrated that the sequential administration of PMSG 
and hCG could induce ovulation and pregnancy in "hypoovarian" women, i.e. 
women with cycle disturbances. 
Unfortunately, humans treated with gonadotrophic preparations from animal 
origin appeared to produce antibodies against the non-primate glycoproteins, 
reducing the clinical effect after repeated administration (Evans and Simpson, 
1950). For this reason, preparations from human origin were developed. Donini 
et al. (1949, 1964) extracted human menopausal gonadotrophin (hMG) from 
urine of postmenopausal women. In 1953, Borth, Lunenfeld and de Watteville 
organized a meeting in Geneva, which was attended by a small group of 
scientists involved in research on gonadotrophins. This meeting resulted in the 
foundation of the so-called Gonadotrophinclub or G-Club. The members of the 
G-Club met every few years and discussed assay problems and clinical ap-
plications of gonadotrophins. In 1958, Gemzell et al. described the induction of 
ovulation in amenorrhoeic women treated with human pituitary follicle-stimula-
ting hormone (FSH). Lunenfeld et al. (1960) and Rosemberg et al. (1963) 
described successful ovarian stimulation with hMG and hCG. The first pregnan-
cies were reported subsequently (Lunenfeld et al., 1962). 
After the first successes with gonadotrophin treatment more clinical experiments 
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started. The major problems concerned the monitoring of ovarian response to 
the therapy, and especially the prevention of hyperstimulation and multiple 
pregnancies. Initially, palpation of ovarian enlargement, vaginal cytology and 
basal body temperature were used to assess the effect of the treatment. Later 
on, also the aspect of the cervical mucus was used as a clinical parameter. The 
development of rapid fluorimetrie assays for the determination of total urine 
oestrogens and, later, immunochemical assay procedures for quantitation of 
17ß-oestradiol (E2) in serum enabled a more reliable monitoring of the treatment 
(Taymor et al., 1970, Tredway et al., 1974). Ultrasonography of follicular 
growth was introduced in the late 1970s (Kratochwil et al., 1972, Hackelöer et 
al., 1977) and is now the most reliable monitoring method, together with serum 
E2 determinations. 
1.2 Structure, assays and function of gonadotrophins 
Structure 
FSH, luteinizing hormone (LH) and hCG are glycoproteins, consisting of two 
polypeptide chains, designated a- and ß-subunit, with several carbohydrate side 
chains. The σ-subunit is virtually identical for FSH, LH and hCG with respect to 
aminoacid composition (Rathnam and Saxena, 1975). It contains 92 amino acids 
and two N-linked carbohydrate groups. The ß-subunit varies and is responsible 
for the specific biological characteristics of FSH, LH or hCG. The ß-subunits of 
FSH and LH contain 111 and 115 amino acids, respectively, with two car-
bohydrate side chains. The ß-subunit of hCG is similar to that of LH, except for 
a carboxyl-terminal extension of 30 amino acids with 4 O-linked oligosac-
charides. The carbohydrate side chains usually terminate with sialic acid. FSH 
contains approximately 5% sialic acid on a weight basis, LH 1 % and hCG 
approximately 12% (Vaitukaitis et al., 1976). The molecular weight of the gly-
coprotein hormones is approximately 29000 daltons (Tausk et al., 1986). 
The two subunits are noncovalently linked by several bonds which stabilize the 
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tertiary structure of the molecule (Chappel et al., 1983). Free α- and ß-subunits 
are not recognized by biological receptor preparations and, therefore, do not 
possess intrinsic biological activity (Grimek and McShan, 1974, Vaitukaitis et 
al., 1976). Only the native molecule is biologically active (Manjunath et al., 
1982, Pierce and Parsons, 1981). The hCG molecule is recognized by the LH 
receptor and exerts similar biological effects as LH (Combarnous et al., 1986, 
Segaloff and Ascoli, 1992). The carboxyl-terminal extension of the ß-subunit is 
thought to cause the prolonged half-life of hCG compared to LH (Matzuk et al., 
1990). 
Gonadotrophin molecules appear to exist in multiple isoforms, with different 
physicochemical and biological properties. The presence of these isoforms has 
been demonstrated by gel filtration and isoelectric focusing techniques (Robert-
son et al., 1977, Sherins er al., 1973). Changes in the carbohydrate side chains 
of the molecule are considered to be responsible for the different properties 
(Tsuruhara et al., 1972, Peckham and Knobil, 1976). For instance, FSH isoforms 
with a high degree of sialic acid residues, the more acidic isoforms, exhibit a 
lower receptor binding activity, longer half-life and lower in-vitro bioactivity than 
the more basic isoforms (Ulloa-Aguirre and Chappel, 1982, Wide and Hobson, 
1986). Relative proportions of each FSH or LH isoform secreted by the pituitary 
gland depend on age and on the endocrine status (Wide, 1989, Peckham et al., 
1973, 1976, Reader et al., 1983). For example, FSH in serum from premeno-
pausal women is less acidic than FSH from postmenopausal women (Wide, 
1982). Thus, the biological activity of FSH and LH secreted by the pituitary can 
be modified. 
Assays 
The activity of the gonadotrophic hormones can be measured by various 
biological and immunochemical assays. Bioassays provide information on 
functional aspects of a hormone, whereas immunochemical assays give infor-
mation on the presence of a certain epitope. In each assay procedure the 
activity of the gonadotrophin is calibrated against an international reference 
preparation or an international standard. 
Immunochemical assays are based on the specific interaction of an antibody 
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with an antigen and provide information on the presence of an antigen in a 
certain sample. In the radioimmunoassay (RIA) a radioactively labelled antigen is 
applied, whereas in the enzyme-linked immunosorbent assay (ELISA) an enzyme 
is used for labelling. In the immunoradiometric assay (IRMA) the antibody is 
radioactively labelled instead of the antigen. A "sandwich" system can be 
developed, using one solid-phase antibody and a second radio- or enzyme-
labelled antibody. The antibodies are directed against different antigenic sites on 
the same molecule, thus improving the specificity of the assay. 
The radio ligand receptor assay or receptor binding assay gives information on 
the interaction between the (radioactively labelled) hormone with its receptor on 
an intact cell or the membrane of a cell. 
The biological activity can be determined either in vivo or in vitro. In-vitro 
bioassays for FSH can be based on the induction of aromatase activity in 
cultured immature rat Sertoli cells or in rat granulosa cells (Van Damme et al., 
1979, Jia and Hsueh, 1986). The in-vitro bioactivity of LH can be measured by 
the induction of testosterone in mouse Leydig cell preparations or by the 
induction of progesterone in cultured Leydig tumour cells (Van Damme et al., 
1974, Dahl and Sarkissian, 1993). The Steelman and Pohley assay for the in-
vivo bioactivity of FSH is based on the ovarian weight gain in immature rats 
after three days of treatment with FSH (Steelman and Pohley, 1953). The in-
vivo bioactivity of LH can be measured by the seminal vesicle assay, which is 
based on the increase in the seminal vesicle weight in immature rats after five 
days of treatment with LH or hCG (Watts and Adair, 1943). The ovarian 
ascorbic acid depletion test is another in-vivo bioassay for LH (Parlow, 1961). 
Formerly, this test was widely used, but it appeared to be non-specific. The in-
vivo bioassays provide information on the activity and also the half-life of the 
administered gonadotrophins. However, they are rather inaccurate and not very 
sensitive. Sensitivity and accuracy is increased in the in-vitro bioassays. 
Function 
At birth, approximately one million healthy primordial follicles are present in the 
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Figure 1. Steroid biosynthetic pathways. 
(adapted from Speroff étal., 1983) 
ovaries (Baker, 1963). Only a very small fraction, about 400 follicles, will 
ovulate during reproductive life, the remaining part will undergo atresia. The 
maturation from primary follicle to preantral, antral and preovulatory follicle is 
estimated to last 85 days (Gougeon, 1982). It is assumed that very low levels 
of gonadotrophins are required for the regulation of tonic growth of follicles up 
to the early antral stage (Adashi, 1991, Gulyas et al., 1977, Ross, 1974). 
Cyclic alterations of gonadotrophins are essential for the exponential growth of 
small antral follicles (with diameters up to 2 mm) to the preovulatory stage, and 
also for ovulation and transition into a corpus luteum (Chikazawa ef al., 1986, 
Vande Wiele ef al., 1970). 
During the luteal phase of the menstrual cycle, the largest healthy follicles are 
Testosterone 
Estradiol 
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4-5 mm in diameter (McNatty et al., 1983). In this stage, LH receptors are only 
present on the cells of the theca interna, whereas granulosa cells possess FSH 
receptors (Zeleznik et al., 1974). LH stimulates the production of androgens (the 
substrate for oestrogens) by the theca interna cells. FSH stimulates mitosis of 
the granulosa cells (Yong et al., 1992a), induces the cholesterol side-chain 
cleavage enzyme which converts cholesterol into pregnenolone (Goldring et al., 
1987), induces the aromatase enzyme in granulosa cells, which converts thecal 
androgens into oestrogens (Erickson and Hsueh, 1978a) and induces LH 
receptors on the granulosa cell (Zeleznik et al., 1974). During the late luteal 
phase of the cycle serum FSH concentrations increase until a certain threshold 
level is reached (Brown, 1978). This rise of FSH levels results in the recruitment 
of a cohort of follicles of 4-6 mm in diameter, which start to grow and gain the 
ability to aromatize androgens into oestrogens. E2 suppresses gonadotrophin 
secretion of the pituitary by a sensitive feedback mechanism (Zeleznik, 1981). 
In addition to E2, granulosa cells of the maturing follicle secrete inhibin, which 
also suppresses FSH levels (Erickson and Hsueh, 1978b, Findlay, 1986). So as 
the follicles mature, FSH levels will drop. The largest (dominant) follicle has 
gained increased sensitivity to FSH during its course of maturation and con-
tinues to grow despite a decreasing FSH concentration (Zeleznik and Kubic, 
1986). The increased sensitivity may be caused by an increase in the number of 
FSH receptors or by the effect of local growth factors (Zeleznik et al., 1974, 
Hammond et al., 1988). The growth of less mature follicles is still dependent on 
high FSH levels, and suppression below the threshold FSH level results in atresia 
of these non-dominant follicles. Paracrine and autocrine growth factors probably 
also play a role in the induction of atresia (Adashi, 1991 , Cahill et al., 1985). 
LH may also play a role in the process of selection of a dominant follicle (Baird, 
1992). The ability of FSH to induce superovulation in hypophysectomized rats 
was inhibited by large amounts of LH (Opavsky and Armstrong, 1989). This 
inhibitory effect could be prevented by administration of the anti-androgen 
hydroxyflutamide (Chandrasekhar et al., 1988). Injection of an antiserum to LH 
increased the ovulation rate in the guinea-pig (Terranova and Greenwald, 1981). 
These results suggest that LH induces follicular atresia by stimulating the 
production of androgens. During the follicular phase of the menstrual cycle LH 
levels increase slightly, probably resulting in increased thecal androgen produc-
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Figure 2. "Two-cell two-gonadotrophin" concept, 
(from: Hsueh era/., 1984) 
tion. The dominant follicle is able to aromatize the androgens, but less mature 
follicles lack the aromatase enzyme. In these follicles increased androgens may 
be converted by 5o-reductase into potent androgens (dihydrotestosterone), 
which induce atresia (Louvet et al., 1975). In a late preovulatory stage, from 
day 9 or 10 of the follicular phase onwards, LH also exerts an effect on granu­
losa cells, after the induction of LH receptors by FSH (Zeleznik et al., 1981). LH 
increases the production of progesterone and oestradiol by the granulosa cells 
18 
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and inhibits cell mitosis (Yong et al., 1992a, 1992b). 
The dominant follicle ovulates in response to the mid-cycle LH surge, and 
subsequently a corpus luteum is formed. Two steroidogenic cell types, small and 
large luteal cells, are present in the corpus luteum. It is assumed that the small 
luteal cells are derived from the theca cells, and the large luteal cells from the 
granulosa cells. They are also referred to as theca-lutein and granulosa-lutein 
cells, respectively (Ohara er al., 1987). Theca-lutein cells synthesize predomi-
nantly progesterone and androgens, although also basal levels of oestrogens can 
be produced. The granulosa-lutein cells produce the major proportion of oestro-
gens, by aromatization of the androgens which are synthesized in the theca-
lutein cells. The granulosa-lutein cells also produce basal levels of progesterone 
and androgens. The "two-cel l" mechanism of oestrogen production in the 
corpus luteum is analogous to that in the preovulatory follicle (Mori et al., 
1992). LH and hCG are the primary luteotropic hormones, stimulating steroido-
genesis in the theca-lutein cells (Fitz et al., 1982, Ohara et al., 1987). Probably, 
LH and hCG also stimulate steroidogenesis in the granulosa-lutein cells (Mc-
Allister et al., 1990, Tsonis et al., 1987, Wickings et al., 1986, Wood et al., 
1993), although contradictory results have been reported as well (Ohara eí al., 
1987). FSH does not influence steroidogenesis in the theca-lutein cells, nor pro-
gesterone and androgen production by the granulosa-lutein cells (Fisch et al., 
1989, Ohara et al., 1987, Wood et al., 1993). Whether aromatase activity in 
the granulosa-lutein cells is stimulated by FSH is still unclear (McAllister et al., 
1990, Ohara et ah, 1987, Tsonis et al., 1987, Wickings et al., 1986, Wood et 
al., 1994). Local paracrine and autocrine factors may influence steroid produc-
tion in the corpus luteum (Armstrong, 1992, Wood et al., 1994). 
Both the number of steroidogenic cells in the corpus luteum and their steroido-
genic capacity diminish progressively during the course of the luteal phase. 
However, steroidogenic responsiveness to hCG increases over the same period 
(Fisch et al., 1989). Thus, the corpus luteum becomes increasingly dependent 
upon gonadotrophic support and will eventually undergo luteolysis. In the case 
of a pregnancy trophoblastic hCG can rescue the corpus luteum from luteolysis. 
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1.3 Clinical applications in the female 
Preparations 
Gonadotropine preparations can be produced in three ways: isolation from 
pituitaries, extraction and purification from urine and, since a few years, via 
recombinant DNA techniques. The use of pituitary gonadotrophic preparations 
has been abandoned, since the source of human pituitaries is limited and also 
because of reports of viral contamination of pituitary human growth hormone 
preparations, resulting in the Creutzfeldt-Jakob disease (Brown et al., 1985). 
Urinary gonadotrophic preparations are still used on a large scale, namely hCG, 
hMG and purified FSH. HCG (Pregnyl, Profasi) is purified from urine of pregnant 
women. This preparation is applied for its LH-like bioactivity, namely to Induce 
ovulation of preovulatory follicles and to stimulate corpus luteum function. 
Gonadotrophic preparations with FSH activity are used to stimulate follicular 
growth. HMG (Humegon, Pergonal) is purified from urine of postmenopausal 
women. Each batch has to contain equal amounts of FSH and LH in terms of its 
in-vivo bioactivity. Due to inherent inaccuracy of bioassays (the Steelman and 
Pohley assay for FSH and the seminal vesicle assay for LH), results of deter-
minations are within 80 and 125% of stated activity. If the LH bioactivity after 
purification of the preparation from urine is lower than required, hCG may be 
added to increase the LH bioactivity (Stokman et al., 1993). A small amount of 
endogenous or exogenous LH is necessary for follicular development with 
sufficient steroid production (Couzinet et al., 1988, Schoot et al., 1992). 
However, the amount of LH activity in hMG is relatively large. The theory that a 
high LH level causes premature luteinization and is detrimental to oocyte quality 
(Howies et al., 1986, Stanger and Yovich, 1985), has led to the development of 
preparations with lower LH activity. Especially in patients with the polycystic 
ovary (PCO) syndrome, having a high endogenous LH to FSH ratio, these 
preparations were supposed to be beneficial. 
If no hCG is added after purification from postmenopausal urine, the ratio of 
FSH to LH bioactivity is 3 : 1 . This preparation is also produced nowadays 
(Normegon). 
In purified FSH preparations (Follegon, Metrodin) LH is almost completely 
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removed after purification from urine by a polyclonal antibody to hCG. The ratio 
of FSH to LH bioactivity is more than 6 0 : 1 . 
Recently, a highly purified urinary FSH preparation (Metrodin-HP) has been deve-
loped, In which urinary protein contaminants are almost completely removed 
using a number of high performance liquid chromatography steps (Giudice et al., 
1994). 
Clinical studies comparing the effect of hMG and purified FSH in PCO patients 
had controversial results (Venturoli et al., 1984, Larsen et al., 1990, McFaul et 
al., 1990, Tanbo et al., 1990), and up to now there is no evidence that purified 
FSH preparations are preferable to hMG. 
Several ¡soforms of FSH and LH have been identified in all urinary preparations 
(Harlin et al., 1986). As mentioned above, the pituitary is able to secrete 
multiple FSH and LH ¡soforms, and it is obvious that also in serum and urine a 
heterogeneity of gonadotrophin molecules is present (Roos, 1968, Robertson et 
al., 1977, Wide, 1982). Separate ¡soforms display different in-vivo and in-vitro 
bioactivity. Differences in the isohormone profile between preparations or 
between batches of the same preparation may result in discrepancies in bioacti-
vity (Harlin era/ . , 1986). 
Recently recombinant human FSH has been produced by a Chinese hamster 
ovary cell line transfected with the human FSH α- and ß-subunit genes (Puregon, 
Gonal-F) (Keene et al., 1989). These preparations are pure and completely 
devoid of LH activity. The molecular mass and the amino acid and carbohydrate 
composition appeared to be very similar to that of natural FSH (De Boer and 
Mannaerts, 1990). The FSH isohormone profile after isoelectric focusing and 
chromatofocusing showed close similarity to that of Metrodin (De Boer and 
Mannaerts, 1990). In-vitro and in-vivo bioactivities were comparable to those of 
urinary or pituitary FSH (Mannaerts et al., 1991). 
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Indications and treatment schedules 
1. Treatment of anovulation 
Gonadotrophic preparations were primarily developed to treat amenorrhoeic or 
anovulatory women suffering from infertility. The objective of the treatment in 
these patients is to induce monofoilicular growth and subsequent ovulation. 
Women with hypogonadotrophic hypo-oestrogenic amenorrhoea and women 
with normogonadotrophic normo-oestrogenic anovulation can be treated with 
gonadotrophins (Group I and II respectively, according to the WHO classification 
of anovulation, Lunenfeld and Insler, 1974). Women of Group I generally 
respond very well to either pulsatile GnRH or hMG treatment. The treatment of 
first choice for women of Group II, most of whom are suffering from the PCO 
syndrome, is clomiphene citrate. If they are resistant to this therapy, gonado-
t rophs treatment can be applied. In this group, lower ovulation and pregnancy 
rates are obtained than in Group I (Dor et al., 1980). The risk of complications 
of the treatment is relatively high, in particular the ovarian hyperstimulation 
syndrome (OHSS) and multiple pregnancies (Oelsner et al., 1978, Schenker et 
al., 1981). It appears to be difficult to effectuate monofoilicular growth, despite 
adequate monitoring of the treatment cycle with ultrasonography and E2 
measurements. During hMG treatment serum FSH concentrations are maintained 
at a high level, above the threshold, for several days. This may result in the 
recruitment and growth of more than one follicle. 
The classical treatment schedule is based on an initial dose of two ampoules of 
hMG (150 IU), which is increased with one ampoule per week until ovarian 
response is observed (Lunenfeld and Insler, 1974). Other treatment schedules 
have been developed to prevent multiple follicular growth and thus reduce the 
risks of OHSS and multiple pregnancies. In the low-dose step-up scheme the 
initial gonadotrophin dose is low (Poison et al., 1987, Hamilton-Fairley et al., 
1991, van der Meer ef al., 1994). If no ovarian response is observed after two 
weeks, the dose is increased with very small steps. If follicular growth is seen, 
the dose is not further increased. Only the follicle which is most sensitive to 
FSH (the dominant follicle) starts to grow and produce E2, while less sensitive 
follicles become atretic. Another treatment regime is the step-down schedule 
(Mizunuma et al., 1991). The initial hMG dose is relatively high. As soon as 
ovarian response is observed, the dose is decreased and FSH levels drop. 
22 
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Follicles which already started to mature have gained increased sensitivity to 
FSH but less mature follicles fail to thrive as FSH levels decrease. Applying the 
low-dose step-up and the step-down methods, the incidence of OHSS and 
multiple pregnancies has considerably decreased (Hamilton-Fairley et al., 1 9 9 1 , 
Mizunuma et al., 1991). 
SINGLE OVULATION MULTIPLE OVULATION - WIDER GATE 
THRESHOLD 
О ATRESIA О 
Figure 3. Model for the selection of a dominant follicle in the early follicular phase 
of the cycle. 
(From: Baird, 1987) 
2. In vitro fertilization 
A second indication for the use of gonadotrophins is the induction of multiple 
follicular growth in in vitro fertilization (IVF) cycles. Relatively high doses of 
gonadotrophins are administered to women with, in most cases, normal ovarian 
function. During the entire stimulation phase of the cycle, FSH concentrations 
are at a high level, and a large cohort of follicles will mature. Multiple oocytes 
will be retrieved at follicle aspiration. The transfer of more than one fertilized 
oocyte into the uterus, and the possibility to cryopreserve supernumerous 
fertilized oocytes increase the success rate of the IVF treatment. 
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In IVF cycles, gonadotrophins can be administered alone or in combination with 
clomiphene citrate (Jones et al., 1984, Rönnberg et al., 1988). Unfortunately, 
applying these treatment schedules, a considerable number of cycles had to be 
cancelled because of premature LH surges and subsequent premature ovulation. 
This problem was solved with the introduction of gonadotrophin releasing 
hormone (GnRH) agonists in IVF in the 1980s (Porter et al., 1984, Neveu et al., 
1987, Smitz et al., 1987). At present, most IVF centres combine GnRH agonist 
and gonadotrophin administration. The GnRH agonist treatment is usually 
started in the luteal phase of the previous cycle. An initial flare-up effect is seen 
with an increase of endogenous FSH and LH concentrations, followed by a 
suppression of pituitary gonadotrophin release. When pituitary suppression is 
sufficient, exogenous gonadotrophic stimulation is started. The GnRH agonist 
administration is continued until the hCG administration prior to oocyte retrieval. 
Thus, the risk of premature ovulation is considerably reduced (Loumaye, 1990). 
3. Other indications 
Gonadotrophin preparations are also being used to improve the quality of 
cervical mucus (Soto-Albors et al., 1989). For this indication, low doses of 
gonadotrophins are administered in the second week of the follicular phase. 
Furthermore, gonadotrophins are applied to induce mild superovulation in 
couples with unexplained infertility or male subfertility (Crosignani et al., 1991, 
Crosignani and Walters, 1994). Gonadotrophin treatment is combined with 
timed intercourse or with intrauterine insemination. The chance to conceive is 
increased by the maturation and ovulation of two or three follicles, instead of 
one. 
Route of administration 
Conventionally, gonadotrophins are administered intramuscularly. The pulsatile 
subcutaneous and the pulsatile intravenous route have been used occasionally in 
non-randomized or non-controlled studies (Edelstein et al., 1990, Ho Yuen et al., 
1984, Kemmann et al., 1983, Nakamura er al., 1989, Prak et al., 1992). The 
pulse frequency of gonadotrophin release by the pituitary would be mimicked. 
The continuous controlled administration might be preferable to a single daily 
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injection. Recently, a randomized study showed that pulsatile subcutaneous 
compared with intramuscular administration did not improve pregnancy rates in 
IVF cycles, despite small differences in pharmacokinetic profiles (De Geyter er 
al., 1994). Randomized studies have not yet been performed to study a possible 
beneficial effect of pulsatile intravenous administration. 
Lately, there has been a number of reports on daily subcutaneous injections of 
gonadotrophins (Howies et al., 1994, Porchet et al., 1994, Wikland et al., 
1994). Particularly recombinant FSH, having no protein contamination, will be 
feasible for subcutaneous administration. Subcutaneous injections may be less 
painful than intramuscular injections and are convenient for selfadministration by 
the patient. 
1.4 Outline of the thesis 
Gonadotrophin preparations have been used in clinical practice during many 
years. The development of sensitive and specific immunoassay procedures for 
the quantitation of FSH, LH and hCG concentrations in serum enable a more 
accurate basic evaluation of the effect of gonadotrophin treatment. New 
gonadotrophic preparations, FSH-dominant urinary preparations and recombinant 
FSH, have been developed. These preparations have to be evaluated in clinical 
studies. Other ways of administration than the intramuscular route are being 
applied nowadays. 
The aims of the present studies were: 
1. to investigate the effect of a single hMG administration on serum FSH, LH 
and hCG concentrations, as determined by sensitive and specific im-
munoassays, during pituitary suppression by a GnRH agonist. The intra-
muscular, intravenous and subcutaneous administration route were 
applied (chapters 2, 3, 4). 
2. to study the effect of daily gonadotrophin administration on follicular 
growth and endocrine parameters in serum and follicular fluid in IVF 
25 
cycles. Urinary preparations with different FSH/LH ratios were compared 
(chapters 6, 8, 9) and the effect of a recombinant FSH preparation was 
studied (chapter 7). The intramuscular, pulsatile intravenous and subcuta-
neous administration routes for gonadotrophins were evaluated (chapters 
5, 7). In all studies a fixed FSH dose was used and gonadotrophs treat-
ment was combined with GnRH agonist administration. 
The effect of daily gonadotrophin administration was studied in IVF 
cycles, because of the possibility to assess the content of follicular fluid 
and oocyte and embryo quality. Only women with normal ovarian func-
tion, as determined by the early follicular endocrine profile, were included 
in the studies. Factors which might influence the effect of ovarian stimu-
lation treatment were eliminated, in particular impaired thyroid function, 
hyperprolactinaemia, unilateral oophorectomy or endometriosis. Couples 
with male subfertility, as judged by semenanalysis or by the fertilization 
rate in a previous IVF cycle, were excluded to be able to compare fer-
tilization rates and embryo quality in the IVF studies. 
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administration of h M G during pituitary suppression 
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Abstract 
This study was undertaken to study the effects of the commonly used ovarian stimu-
lation regimen on gonadotrophin levels. The behaviour of follicle-stimulating hormone 
(FSH), luteinizing hormone (LH) and human chorionic gonadotrophin (hCG) was studied 
after intramuscular (i.m.) and intravenous (i.v.) human menopausal gonadotrophin 
(hMG) administration. 
Six female volunteers participated in the study. During pituitary suppression with a 
gonadotrophin-releasing hormone (GnRH) agonist (buserelin), a single dose of hMG (150 
IU) was injected i.m. or i.v., in a cross-over design with an interval of two weeks. Blood 
samples were collected frequently after the injection. Serum concentrations of FSH, 
specific LH and hCG were determined. 
After i.m. administration of hMG a peak FSH concentration of 7.4 ± 1 . 3 U/L was 
reached after 8 (6-24) hours with a subsequent decrease. Half an hour after i.v. 
administration peak FSH values of 30.5 ± 5.6 U/L were obtained, followed by a 
decrease to baseline levels within 48 hours. Exogenous LH and hCG were hardly 
detectable after i.m. administration of hMG. Half an hour after i.v. injection of hMG a 
small increase in specific LH levels to 6.7 ± 2.6 U/L was shown followed by a decline. 
hCG concentrations increased after i.v. hMG administration to 7.6 ± 1.6 U/L. 
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Introduction 
Gonadotropic preparations have been used in clinical practice for many years, 
mainly for stimulation of follicular growth and induction of ovulation (Gemzell er 
al., 1958, Schwartz and Jewelewicz, 1981). These preparations contain follicle-
stimulating hormone (FSH)- and luteinizing hormone (LH)-activities. FSH and LH 
are isolated primarily from urine of postmenopausal women. Since the amount 
of LH is not sufficient to reach an FSH/LH ratio of 1, human chorionic gonado-
t r o p i n (hCG), purified from urine of pregnant women, may be added in small 
amounts to the preparation to reach the necessary LH in-vivo-bioactivity (Vemer 
and Sanders, 1989). 
Although many women have been treated with these gonadotrophic prepara-
tions for over 25 years, relatively little is known about their kinetic behaviour 
after injection: how high are the peak concentrations and how fast are they 
reached, which is the decrease rate after injection? Previously published studies 
reported on pharmacokinetics of endogenous gonadotrophins (Yen et al., 1968, 
1970) or gonadotrophins purified from human pituitaries (Amin and Hunter, 
1970, Kjeld et al., 1976). Hormones isolated from urine, however, might exert 
very different kinetic properties (Harlin era/ . , 1986). Two of the studies on phar-
macokinetics of urinary gonadotrophins reported on males (Mizunuma et al., 
1990, Jockenhövel et al., 1990) while Sharma et al. (1987) investigated the 
pharmacokinetics of a purified FSH preparation in women with suppressed 
pituitary function. Diczfalusy and Harlin (1988) investigated the pharmaco-
kinetics of gonadotrophins also in women after a single intravenous (i.v.) or 
repeated intramuscular (i.m.) administration, but they did not suppress the 
endogenous gonadotrophin activity, which complicated the estimation of the 
half-life of LH. The effect of administration of human menopausal gonadotrophin 
(hMG) on serum hCG concentrations has never been reported. 
In clinical practice, in women undergoing ovarian stimulation treatment, routine-
ly daily i.m. injections of hMG are administered, often during pituitary suppres-
sion by a gonadotrophin-releasing hormone (GnRH) agonist (Neveu et al., 1987). 
Recently, pulsatile i.v. administration of hMG has been used for ovarian stimula-
tion, which would mimic the physiological release of pituitary hormones (Ho 
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Yuen et al., 1989, Edelstein et al., 1990). 
The present study investigates for the first time the effect of a single i.m. and 
i.v. administration of hMG in a group of women during pituitary suppression, on 
serum FSH, LH and hCG levels. 
Methods 
Study design 
Six healthy female volunteers participated in the study, having regular menstrual 
cycles of 26-30 days, t w o ovaries, normal early follicular levels of FSH, LH, 
prolactin, testosterone and thyroxin, and not having used sex steroids in the 
three months prior to the study. The age of the women varied from 28 to 35 
years, their median height was 1.68 m (1.65-1.73) and their median weight 63 
kg (55-95). The body mass index varied from 19.5 to 35.0 kg/m2 (median value 
21.5 kg/m2). The study was approved by the Ethical Committee of the hospital. 
Written informed consent was given. 
On day 21 of the cycle intranasal administration of the GnRH agonist buserelin 
(Suprefact, Hoechst Holland N.V., Amsterdam, The Netherlands) was started in 
a dose of 300 μg three times per day. If the serum oestradiol (E2) concentration 
on the tenth day of buserelin administration was below 500 pmol/L, pituitary 
suppression was considered sufficient. If the E2 level was above 500 pmol/L, 
the E2 determination was repeated two or three days later until the required low 
concentration was reached. Buserelin was continued during the entire study 
period. 
Between 8.00 and 9.00 a.m. on the day after the E2 level was below 500 
pmol/L, 150 IU hMG (Humegon, Organon Int. B.V., Oss, The Netherlands) were 
injected intramuscularly (i.m.) or intravenously (i.V.). The first hMG admini­
stration was i.m. in three women and i.v. in the other three women. Two 
different batches of Humegon were used, with similar FSH- (82 IU per ampoule) 
and LH in-vivo bioactivity (66 and 61 IU per ampoule, respectively). Immediately 
before the hMG injection and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 96 hours 
and one week after hMG administration blood samples were collected. Blood 
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samples were centrifuged within 15 minutes (5 minutes at 2500xg) and the sera 
were stored at -20eC until assayed. After a washout period of two weeks a 
second injection of 150 IU hMG was given using the other route of admini-
stration. The same protocol for the collection of serum samples was performed. 
One week after the second hMG injection buserelin administration was discon-
tinued. 
Assays 
The serum E2 concentration on the tenth day of buserelin treatment was 
determined by a time-resolved fluoroimmunoassay (DELFIA, Wallac Oy, Turku, 
Finland). The limit of 500 pmol/L was chosen because of the low sensitivity of 
the assay in the range from 1 50 to 500 pmol/L. The E2 concentration imme-
diately before the first hMG injection was measured retrospectively by a more 
sensitive radioimmunoassay (Thomas et al., 1977). 
Serum concentrations of FSH, specific LH and hCG were measured by applying 
time-resolved fluoroimmunoassays (DELFIA, Wallac Oy, Turku, Finland). These 
tests are solid phase, two-site assays in which two monoclonal antibodies are 
directed against two separate antigenic determinants on the hormone. The 
assays only detect intact molecules. Serum samples are first reacted with 
immobilised monoclonal antibodies directed against a specific antigenic site on 
the ß-subunit of the hormone. Europium-labelled antibodies directed against a 
specific antigenic site on the a- or ß-subunit are then reacted with the molecule, 
already bound to the solid phase antibody. After dissociation of the Europium-
ions from the labelled antibody, the amount of fluorescence is measured. 
The assay for FSH had a detection limit of 0.05 U/L, with an intra-assay and 
inter-assay variation of less than 5%. The assay for specific LH had a crossreac-
tivity with hCG of less than 1.5 %. The detection limit for specific LH was 0.05 
U/L, the intra-assay variation was less than 6%, the inter-assay variation less 
than 8%. The hCG assay had a crossreactivity for LH of less than 0.5%. The 
detection limit was 0.5 U/L, the intra-assay variation less than 10%, the inter-
assay variation less than 11 %. 
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Statistics 
All data are presented as mean values with the standard error of the mean. 
Table 1. Mean basal (C0) and maximal (C,m„) concentrations of serum FSH, 
specific LH and hCG (with standard error) after a single i.m. or i.v. 
administration of 150 IU hMG, in six healthy women during pituitary 
suppression with buserelin; and the median interval after injection (t„,„, 
hours) before reaching the peak value, with the range in parentheses. 
serum FSH 
serum LH spec 
serum hCG 
i.m. 
i.v. 
i.m. 
i.V. 
i.m. 
i.v. 
3.8 ± 1.1 U/L 
4.4 ± 1.5 U/L 
3.7 ± 1.8 U/L 
3.5 ± 1.7 U/L 
<0.5 U/L 
<0.5U/L 
8 (6-24) h 
0.5 h 
96 (0.5-168) h 
0.5 (0.5-96) h 
-
0.5 (0.5-1) h 
7.4 ± 1.3 U/L 
30.5 ± 5.6 U/L 
5.2 ± 2.7 U/L 
7.0 ± 2.6 U/L 
-
7.6 ± 1.6 U/L 
Results 
The mean period of buserelin administration before reaching the E2 limit of 
< 5 0 0 pmol/L was 13 ± 2.9 days. The mean E2 concentration immediately 
before the first hMG injection, as measured by radioimmunoassay, was 203 ± 
107 pmol/L. One woman completed the first series of blood sampling after i.v. 
hMG administration, but did not wish to continue the study. Therefore data 
were obtained from six women after i.v. administration and from five women 
after i.m. administration. The wash-out period between the two routes of 
administration appeared to be long enough. 
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Figure 1. Mean FSH concentrations in five women after i.m. injection (A) and in six 
women after i.v. injection (B) of 150 IL) hMG, during GnRH agonist 
administration. 
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Mean specific LH concentrations in serum in five women after i.m. 
injection (A) and in six women after i.v. injection (B) of 150 IU hMG, 
during GnRH agonist administration. 
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FSH concentrations after ¡.m. and i.v. administration of a single dose of hMG are 
presented in Figure 1 and Table 1. The mean FSH concentration at 48 hours 
both after i.m. and i.v. injection did not differ from the FSH concentration before 
injection (4.6 ± 0.9 U/L and 3.6 ± 0.6 U/L, respectively). 
Specific LH concentrations in serum, measured without crossreactivity with 
hCG, after i.m. and i.v. administration of a single dose of hMG are presented in 
Figure 2 and Table 1. In the first half hour after i.m. administration of hMG the 
patterns differed: in two women LH concentrations increased, in three women 
no increase was seen. After the first half hour a decrease of LH concentrations 
was present in all women, until 6 hours after injection when LH concentrations 
returned to baseline values. Following the initial rise of LH concentrations after 
i.v. injection to 6.7 ± 2.6 IU/L, a decrease to 2.1 ± 1.0 U/L at 4 hours after 
injection was present. After this decrease, LH concentrations returned to 
baseline levels. 
After i.m. administration of hMG, hCG concentrations hardly exceeded the 
detection limit of the assay. Serum hCG concentrations after i.v. administration 
are presented in Table 1. 
Discussion 
After i.m. administration of hMG serum FSH levels showed a smaller and more 
prolonged increase than after i.v. administration. The explanation is the for-
mation of an intramuscular depot of hMG, with a gradual release into the 
systemic circulation. Since the absorption process from the intramuscular depot 
would continue during the elimination of the previously absorbed amount of 
hMG, the decrease of FSH levels after i.m. administration was slower than after 
i.v. administration. 
Results of previous studies in male subjects by Mizunuma et al. (1990) and by 
Jockenhövel et al. (1990) were in accordance with our results in females. Mizu-
numa et al. administered a single i.m. dose of hMG and urinary FSH. They 
described a peak FSH value 7-8 hours after injection and a half-life of 36 and 
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32.6 hours, respectively. Jockenhövel et al. described a peak FSH value 10 
hours after the i.m. administration of urinary FSH, and a half-life of 24.6-36.2 
hours. Sharma et al. (1987) and Diczfalusy and Harlin (1988) performed studies 
in women. Sharma et al. determined FSH after a single i.m. injection of purified 
urinary FSH during buserelin administration. They observed peak FSH levels 
between 6 and 18 hours after injection, and a decline of FSH starting 24 hours 
after injection. Diczfalusy and Harlin measured FSH after a single i.v. admini-
stration of hMG without pituitary suppression. They observed a rapid decay with 
a half-life of 1.6 hours and a slow phase with a half-life of 11 hours. Our study 
and the studies by Jockenhövel et al. and Sharma et al. differ from the other 
mentioned studies in the application of a more sensitive assay. 
We were able to differentiate between the LH and hCG component in hMG by 
applying two specific assays. Diczfalusy and Harlin (1988) mentioned the 
difficulty in interpreting serum LH concentrations because of the presence of 
endogenous LH and the relatively low amount of administered LH. We met the 
same problem in our study, despite the administration of buserelin. The mea-
sured LH activity after i.m. hMG administration was probably merely endoge-
nous LH. The decrease of specific LH concentrations shortly after i.m. injection 
was previously described by Diczfalusy and Harlin (1988). Anderson et al. 
(1989) saw a decrease in serum LH levels after an i.m. injection with purified 
FSH, but not after an i.m. hMG injection. The most likely explanation for this 
decrease is a negative feedback mechanism at the hypothalamo-pituitary-ovarian 
axis. Exogenous FSH and LH activity may have stimulated the ovaries to 
produce E2, which In turn had a suppressive effect on the pituitary FSH and LH 
secretion (Richards et al., 1976). The decrease of endogenous FSH could not be 
seen in the serum levels because of the presence of exogenous FSH. We 
consider the second LH rise in several women to be not a real rise but the return 
to baseline levels. Several other authors investigated the pharmacokinetics of 
LH. Yen et al. (1968) described a double exponential disappearance curve of 
serum LH following surgical hypophysectomy in two women, Kjeld et al. (1976) 
determined a half-life of 2.3 hours after i.v. infusion of pituitary LH in males. 
Their study designs were not comparable to ours, and differed more from the 
daily clinical practice. 
In other studies the pharmacokinetics of hCG were investigated. Damewood et 
al. (1989) studied the disappearance of i.m. administered hCG. In our study the 
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dose of hCG ¡η hMG was too low to detect hCG in serum after i.rn. injection. 
Wide et al. (1968) administered hCG intravenously and measured serum hCG 
concentrations by RIA. They calculated a half-life between 6 and 10 hours, 
which is in agreement with our results. 
In conclusion, we described for the first time the different patterns of serum 
FSH levels after a single i.m. or i.v. injection of hMG during pituitary suppres­
sion. Luteinizing hormone and hCG were hardly detectable after i.m. administra­
tion, but showed a demonstrable increase after i.v. injection. 
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Abstract 
Subcutaneous (s.c.) administration of gonadotropic preparations has recently been 
introduced for ovarian stimulation treatment. However, little is known about the 
pharmacokinetics of these preparations after administration by this route. The present 
study therefore investigates the effect of a single dose of human menopausal gonado-
t ropin (hMG) on serum follicle-stimulating hormone (FSH) and luteinizing hormone (LH) 
concentrations. 
Six healthy female volunteers, aged 20-40 years, with regular menstrual cycles and 
normal endocrine profiles, who were not receiving any hormonal medication, were 
treated with the gonadotrophin-releasing-hormone agonist buserelin to suppress 
endogenous gonadotrophin release One volunteer dropped out during treatment. When 
the serum oestradiol concentration had fallen to below 500 pmol/L, an injection of 150 
IU hMG (Humegon) was given subcutaneously Immediately before injection and 0.5, 1, 
2, 3, 4, 6, 8, 10, 12, 15, 20, 24, 48 and 96 hours subsequently, blood samples were 
drawn for the determination of FSH and LH concentrations. 
The baseline FSH level was 2.8 IU/L, and peak concentration (6.8 IU/L) was reached 12 
hours after hMG injection (median values). Exogenous LH could not be measured 
because of the presence of endogenous LH. 
The pattern of serum FSH concentrations after a single injection of hMG was found to 
resemble that seen after intramuscular hMG administration, although the peak FSH 
value was reached somewhat later. 
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Gonadotrophic preparations, such as human menopausal gonadotrophin (hMG), 
are usually administered via the intramuscular (i.m.) route. The recent develop­
ment of gonadotrophic preparations of high purity, especially recombinant 
human follicle-stimulating hormone (FSH), enables subcutaneous (s.c.) admi­
nistration. Compared with i.m. administration, s.c. injections are less painful and 
self-administration by the patient is more feasible. The most appropriate dosage 
interval for s.c. administration is not known, since information is sparse regar­
ding the pharmacokinetics of exogenous FSH and luteinizing hormone (LH) after 
s.c. gonadotrophin injection. We therefore decided to study the effect of a 
single s.c. hMG injection on serum FSH and LH concentrations in female volun­
teers. Since the presence of high levels of endogenous FSH and LH complicates 
interpretation of the results, pituitary function was suppressed by administering 
the gonadotrophin-releasing-hormone (GnRH) agonist buserelin. 
Materials and methods 
Six female volunteers participated in the study. The inclusion criteria were as 
follows: age 20-40 years, a regular menstrual cycle (between 24 and 35 days), 
a normal endocrine serum profile in the early follicular phase of the cycle (FSH 
concentration below 8 IU/L, LH/FSH ratio less than 3, testosterone con­
centration below 2.5 nmol/L, prolactin concentration below 750 mlU/L and 
thyroxine concentration between 58 and 148 nmol/L) and no intake of hormonal 
medication, including oral contraceptives, for at least three months prior to the 
study. The median age of the five volunteers who completed the study was 29 
years (range 29 - 38 years) and the median body mass index was 20.4 kg/m2 
(18.4- 27.3 kg/m2). 
All the women were treated with the GnRH-agonist buserelin (Suprefact nasal 
spray, Hoechst A.G., Frankfurt, Germany) at a dose of 300 лд three times a 
day, from day 21 of the previous menstrual cycle onwards. On day 10 of the 
buserelin treatment, the serum 17ß-oestradiol (E2) concentration was determined 
and then measured every three or four days until it was below 500 pmol/L. One 
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volunteer dropped out during the buserelin treatment because of sinusitis and 
nasal bleeding. As soon as the E2 concentration was found to be below 500 
pmol/L, a single subcutaneous injection of 150 IU Humegon (NV Organon, Oss, 
Netherlands) was given the next day at 8 a.m. and the buserelin treatment was 
continued. Two ampoules of Humegon were diluted in 0.5 mL solvent and 
injected subcutaneously in the abdomen using a syringe injector (Monoject, 
Sherwood Medical, St. Louis, USA). Each ampoule contains 75 IU FSH and 75 
IU LH activity, as determined by in-vivo bioassays. Due to inherent inaccuracy 
of bioassays, results of determinations are within 80 and 125% of stated 
activity. One batch of Humegon was used for the study. 
Blood samples were collected, either by venipuncture or via an intravenous 
cánula, immediately before injection and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 15, 20, 
24, 48 and 96 hours subsequently. Buserelin administration was stopped after 
the last blood samples were taken. The samples were centrifuged within 3 hours 
after collection and serum was frozen at -20°C until assayed. 
The serum E2 concentration on the tenth day of buserelin treatment was 
determined by a time-resolved fluoroimmunoassay (Delfia, Wallac Oy, Turku, 
Finland). The limit of 500 pmol/L was chosen because of the low sensitivity of 
the assay in the range from 1 50 to 500 pmol/L. The E2 concentration imme-
diately before the hMG injection was measured retrospectively by a more 
sensitive radioimmunoassay (Thomas et al., 1977). FSH and LH concentrations 
were determined in all serum samples by immunoradiometric assays (IRMAs), as 
previously described (Kremer et al., 1991). 
Statistical analysis was performed using the Wilcoxon signed-rank test. 
Results 
The median E2 concentration immediately before the hMG injection, as measured 
by radioimmunoassay, was 88 pmol/L (range <75 - 390 pmol/L). The median 
values of the FSH and LH concentrations and the 10th and 90th percentiles, 
before and after Humegon injection, are shown in Figures 1 and 2 respectively. 
The median FSH concentration before injection was 2.8 IU/L (10th percentile 
(p10) 1.4 IU/L; 90th percentile (p90) 4.9 IU/L). Median FSH concentrations started 
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Figure 1 Median serum FSH concentrations and 10th and 90th percentiles after a 
single subcutaneous injection of 150 IU hMG during pituitary suppression 
by buserelin, in five female volunteers. 
to increase within the first half hour after injection and reached a maximum 
value of 6.8 IU/L (p 1 0 4.7 IU/L; p 9 0 7.0 IU/L) after 12 hours (p 1 0 10 hours; p 9 0 12 
hours), the increase being statistically significant (p < 0 . 0 5 ) . Serum LH con­
centrations remained at a low level throughout the study. A small increase in 
median LH concentrations was seen in the first two hours after the Humegon 
injection, but there was great interindividual variation and the increase was not 
statistically significant. 
The subcutaneous injections were well tolerated. Two patients experienced 
transient pain at the injection site, starting 7 and 10 hours after injection, 
respectively, and lasting for a few hours. In one of these t w o patients the 
injection site showed redness without swelling (diameter of red area 1 to 2 cm). 
The symptoms were not severe in either case. 
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Figure 2 Median serum LH concentrations and 10th and 90th percentiles after a 
single subcutaneous injection of 150 IU hMG during pituitary suppression 
by buserelin, in five female volunteers. 
Discussion 
Subcutaneous administration of 150 IU hMG leads to an increase in serum FSH 
concentrations which reach a peak approximately 12 hours after injection and 
gradually decrease thereafter. In a previous study of similar design the effect of 
a single i.m. or i.v. injection of 150 IU hMG on serum FSH and LH levels was 
described (Duijkers et al., 1995). The increase in serum FSH levels after i.m. 
injection of hMG showed a substantially similar pattern to that following s.c. 
injection, although the peak concentration seemed to occur somewhat earlier (8 
hours after i.m. injection as against 12 hours after s.c. injection). 
In a study by Le Cotonnec et al. (1993) serum FSH concentrations were 
determined in male subjects after single i.m. and s.c. injections of 150 IU highly 
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purified urinary FSH (Metrodin HP). These investigators found similar patterns of 
FSH concentrations after s.c. and i.m. administration, wi th maximum con-
centrations occurring 13 and 18 hours after i.m. and s.c. injection respectively. 
In a study by Saal et al. (1991) pharmacokinetic parameters were described 
after single s.c. and i.m. injections of human chorionic gonadotrophin (hCG) in 
male subjects. Serum hCG concentrations reached a peak value 6 and 16 hours 
after i.m. and s.c. injection respectively, the half-lives being 31 ± 3 and 38 ± 3 
hours. The authors concluded that diffusion of hCG into the circulation was 
slower after s.c. administration. These investigations differed from ours as 
regards the groups studied (male instead of female subjects) and the prepara-
tions administered (highly purified FSH and hCG respectively instead of hMG). 
Nevertheless, serum concentrations showed a slightly slower and more pro-
longed increase after s.c. administration than after i.m. administration in all 
studies. 
Serum LH concentrations were insufficiently suppressed to enable exogenous 
LH to be measured. There was great interindividual variation in the serum LH 
profiles and no clear pattern could be seen. 
In the present study, a single s.c. hMG injection was well tolerated by all 
subjects. Repeated s.c. injections with hMG might induce local skin reactions, 
such as swelling, redness or induration, since the urine-derived hMG prepara-
tions are of low purity and contain a large number of non-gonadotrophin 
proteins (Giudice et al., 1994). However, recently a recombinant human FSH 
preparation has been developed, which is of very high purity (Mannaerts et al., 
1991). In contrast with hMG, recombinant human FSH will be very suitable for 
daily s.c. administration. 
Since the FSH profile after s.c. injection showed that serum concentrations 
remained adequate over a period of 24 hours, subcutaneous gonadotrophin 
injections can presumably be given once daily. This assumption is supported by 
the findings of Howies er al. (1994), who treated in vitro fertilization patients 
with a highly purified urinary FSH preparation which was administered once 
daily subcutaneously. This treatment schedule appeared to be effective in 
stimulating multiple follicular development. The injections were also well tolera-
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ted. A pharmacokinetic study now needs to be carried out to measure serum 
FSH concentrations after repeated s.c. gonadotrophin injections. 
It may be concluded from the results of the present study that once-daily 
subcutaneous administration of gonadotropins induces adequate serum con-
centrations of FSH and LH. 
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Chapter 4 
Pharmacokinetics of two human menopausal 
gonadotrophin preparations after single intravenous 
administration during pituitary suppression 
U.M. Duijkers, M.C. Beerens, H.J.T. Coelingh Bennink, J.A.M. Huisman, 
F. Rombout, H.M. Vemer 
Hum. Reprod. 10: 1367-1372, 1995 
Abstract 
A randomized study was performed ¡η nine healthy women, to investigate pharmaco­
kinetic parameters and bioequivalence of two human menopausal gonadotrophin (hMG) 
preparations after intravenous (i.v.) administration. Endogenous gonadotrophin activity 
was suppressed by triptorelin administration. 225 IU of Humegon and Pergonal were 
injected intravenously in a cross-over way with an interval of one week. Blood samples 
were collected very frequently and serum concentrations of follicle-stimulating hormone 
(FSH), luteinizing hormone (LH), specific LH, and human chorionic gonadotrophin (hCG) 
were determined by fluoroimmunoassays. Serum LH bioactivity was measured by an in­
vitto bioassay. 
The area under curve (AUC) and half-life of FSH were 431.5 IU.h/l and 22.20 h for 
Humegon, and 402.6 IU.h/l and 21.33 h for Pergonal. For both preparations, the (total) 
LH immunoactivity and in-vitro bioactivity of serum LH were very similar, and appeared 
to be a composite of specific LH and hCG activity. The area under data of specific LH 
was 17.50 IU.h/l for Humegon and 21.79 IU.h/l for Pergonal, respectively. The AUC 
and half-life of hCG were 153.7 IU.h/l and 14.80 h for Humegon, and 134.1 IU.h/l and 
12.11 h for Pergonal. 
The two preparations were bioequivalent with respect to FSH and hCG immunoreac-
tivity. Bioequivalence could not be proven for LH activity because of the small number 
of subjects. 
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Introduct ion 
In clinical practice today the use of gonadotrophic preparations is widespread. 
These preparations, in particular human menopausal gonadotrophs (hMG), are 
effective in stimulating ovarian function and inducing multiple follicular growth. 
Human menopausal gonadotrophs is derived from urine of postmenopausal 
women and contains follicle-stimulating hormone (FSH) and luteinizing hormone 
(LH) activity. Human chorionic gonadotrophin (hCG) is added to, c.q. present in 
the preparations to obtain the necessary 75 IU LH in-vivo bioactivity per 75 IU 
of FSH (Stokman étal., 1993). 
Several pharmacokinetic studies measuring serum FSH, and sometimes LH, 
levels after administration of FSH or hMG preparations were performed previous-
ly, for instance by Amin and Hunter (1970), Sharma et al. (1987), Diczfalusy 
and Harlin (1988), Anderson et al. (1989), Jockenhövel étal. (1990), Mizunuma 
et al. (1990) and Urban eí al. (1991). The designs of these studies differed: 
some studies were performed in male, other in female subjects, some in hypofy-
sectomized or pituitary down-regulated subjects, some authors used gonado-
trophic preparations isolated from pituitaries, others used urinary FSH or hMG. 
In many previous studies radioimmunoassays (RIA) were applied to measure 
serum FSH (and LH) levels. Recently highly sensitive and specific assays for the 
measurement of gonadotrophic hormones in serum have been developed (immu-
noradiometric and fluoroimmunoassays), making more reliable pharmacokinetic 
data possible. With these assays, a differentiation between the LH and the hCG 
component in hMG can be made. 
We decided to perform a pharmacokinetic study applying fluoroimunoassays. 
We investigated single dose pharmacokinetic parameters and bioequivalence of 
two hMG preparations in a randomized cross-over study in healthy women. 
Since previous studies showed that determination of the exogenous LH com-
ponent in serum after intramuscular (i.m.) administration of gonadotrophic 
preparations is difficult, because of the short half-life of LH and the interference 
of endogenous LH (Diczfalusy and Harlin, 1988), we decided to investigate 
pharmacokinetics after intravenous (i.v.) administration, during suppression of 
pituitary function by triptorelin. FSH, LH and hCG immunoreactivity in serum 
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were determined, as well as LH ¡n-vitro bioactivity. 
Materials a n d m e t h o d s 
Study design 
Nine healthy volunteers participated in the study. The most important inclusion 
criteria were: age between 18 and 40 years; regular menstrual cycle; no former 
treatment with hMG and normal body weight. Exclusion criteria were: endocrine 
abnormalities; hypertension; chronic cardiovascular, hepatic, renal or pulmonary 
disease; abuse of alcohol or drugs; use of drugs interfering with hepatic func-
tion; smoking more than 10 cigarettes per day and use of antioestrogenic or 
investigational drugs within three months prior to the study. The Ethical Com-
mittee of the hospital gave its approval of the study. All women gave their in-
formed consent in writ ing. Before entering the study they had a general physical 
and gynaecological examination, ultrasonography and routine haematology, 
blood biochemistry and urinanalysis. Between day 20 and 25 of the menstrual 
cycle an i.m. injection of 3.75 mg gonadotrophin releasing hormone (GnRH) 
agonist triptorelin (Decapeptyl-CR 3.75, Ferring B.V., Haarlem, The Netherlands) 
was given to suppress endogenous gonadotrophin release. 
From day 10 through 14 after the triptorelin injection, serum FSH and LH 
concentrations were determined by immunoradiometric assays (IRMAs). If the 
difference in FSH and LH concentrations between day 13 and day 14 was not 
greater than the intra-assay variation and the serum oestradiol (E2) concentration 
as measured by RIA did not exceed 200 pmol/L, on day 16 either 225 IU 
Humegon (N.V. Organon, Oss, The Netherlands) or 225 IU Pergonal (Serono, 
Pharma-lmport B.V., Haarlem, The Netherlands) was injected intravenously. One 
week after this injection a second injection with the other preparation was 
given. The preparations were given in random order. 
Blood samples were collected at the following time points: immediately before 
triptorelin injection and 168, 240, 264, 288, 312, 336 hours after triptorelin 
injection. Immediately before the first hMG injection; 5, 10, 15, 20, 30, 45 
minutes and 1, 1.5, 2, 3, 4, 6, 8, 12, 15, 24, 36, 48, 72, 96, 120, 144 hours 
after the first hMG injection. Immediately before the second hMG injection; 5, 
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10, 15, 20, 30, 45 minutes and 1, 1.5, 2, 3, 4 , 6, 8, 12, 15, 24, 36, 48, 72, 
96, 120, 144, 168, 336, 504, 672, 840 hours after the second hMG injection. 
FSH, LH, specific LH and hCG immunoactivity were measured at all time points 
by time-resolved fluoroimmunoassays (DELFI As). Progesterone (P) con-
centrations were measured by RIA at the following time points: immediately 
before and 168 and 336 hours after triptorelin injection, before the second hMG 
injection and 168, 336, 504, 672 and 840 hours after the injection. E2 con-
centrations were measured by RIA at the same time points as P, furthermore 12, 
24, 48, 96, 120 and 144 hours after the first hMG injection, and 12, 24, 48, 
72, 96, 120 and 144 hours after the second hMG injection. LH bioactivity was 
determined at all time points. 
Blood samples were collected by puncturing the cubital vein or by using an 
intravenous cánula in the forearm. The hMG injections were given i.v. in the 
other arm. The volunteers had bed-rest for 12 hours after the hMG administra-
tion. Blood pressure, heart rate and weight were checked several times during 
the study; routine haematology, blood biochemistry and routine urinanalysis 
were checked after completion of the study. 
One batch of each preparation was used for the study. The numbers of the used 
batches of Humegon and Pergonal were CP 092005 and CP 092001 respecti-
vely. The in-vivo bioactivity of the Humegon batch was 67 IU FSH and 80 IU 
LH, of the Pergonal batch 72 IL) FSH and 73 IU LH. The immunoreactivity of 
FSH, LH, specific LH and hCG in ampoules of the used batches was determined 
by DELFIA. 
Data analysis 
For each woman the difference between the baseline value and the actual value 
was used for calculation. Except for specific LH, pharmacokinetic parameters 
were calculated by means of non-linear regression analysis, using the two-
compartment model: concentration (time) = c,*e I L 1 ,"™1 + c2*e1"1-2""™1, where Ci 
is the zero-time intercept (or coefficient) of phase i, and L, is the slope of phase 
i. The area under curve from zero to infinity (AUC) was calculated using the 
following equation: AUC,,.,, = 0,/L, + C2/L2. The elimination half-life (t1/2) was 
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calculated from the slope of the second phase of the disappearance curve: t1;2 
= ln(2)/L2. For specific LH, the area under curve from zero up to the last 
measurable sampling time (area under data, AUD) was calculated. Since 
baseline-correction was not possible for specific LH due to the large variation in 
baseline levels, regression analysis was not performed for this hormone. For 
each hormone parameter, the AUC and AUD were corrected for differences in 
contents of the ampoules used. 
Sequence, period and treatment effects were tested using an Analysis of 
Variance (ANOVA). For AUCQ., , , AUD and t1/2 the ANOVA was performed on the 
log-transformed values. As a decision-making criterium for bioequivalence 
testing the 90% confidence interval for the true ratio "test/reference" based on 
the classical ANOVA was constructed (Humegon administration was designated 
as test treatment and Pergonal administration as reference treatment). A 
parameter was considered bioequivalent when the 90% confidence interval of 
the parameter's true ratio "test/reference" was fully contained within the 
bioequivalence range taken as 0.80-1.25 for the parametric test (on log-trans-
formed parameters). 
Assays 
Serum FSH and LH concentrations between day 10 and day 14 after the 
injection of triptorelin were measured by IRMAs (Medgenix, Fleurus, Belgium), 
as previously described (Kremer et al., 1991). At all time points FSH, LH, 
specific LH and hCG concentrations were measured by DELFIAs (Wallac Oy, 
Turku, Finland). These tests are solid phase, two-site assays in which two 
monoclonal antibodies are directed against two separate antigenic determinants 
on the hormone. Serum samples are first reacted with immobilised monoclonal 
antibodies directed against a specific antigenic site on the ß-subunit of the 
hormone. Europium-labelled antibodies directed against a specific antigenic site 
on the a- or ß-subunit are then reacted with the molecule, already bound to the 
solid phase antibody. After dissociation of the Europium-ions from the labelled 
antibody, the amount of fluorescence is measured. 
The assay for FSH had a detection limit of 0.05 U/L, with an intra-assay and 
inter-assay variation of less than 5%. The standards were calibrated against the 
2nd International Reference Preparation (IRP) of pituitary FSH/LH (interstitial cell-
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Figure 1. Mean baseline-corrected serum FSH concentrations after a single intrave­
nous injection of 225 IU of Humegon and Pergonal during triptorelin 
administration in nine healthy female volunteers. 
LHspec (IU/L) 
во во 
Time (h) 
-•"Humegon -°- Pergonal 
Figure 2. Mean baseline-corrected serum specific LH concentrations after a single 
intravenous injection of 225 IU of Humegon and Pergonal during trip­
torelin administration in nine healthy female volunteers. 
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Figure 3. Mean serum hCG concentrations after a single intravenous injection of 
225 IU of Humegon and Pergonal during triptorelin administration in nine 
healthy female volunteers. 
stimulating hormone) human for bioassay (78/549). The assay for total LH had a 
high crossreactivity with hCG, whereas the assay for specific LH had a cross-
reactivity with hCG of less than 1 % . The detection limit for total LH was 0.12 
U/L, the detection limit for specific LH was 0.05 U/L. In both assays the intra-
assay variation was less than 6%, the inter-assay variation less than 8%. The 
standard preparations were calibrated against the 1st IRP of human LH for 
immunoassay (68/40) for the total LH assay, and the WHO 2nd International 
Standard for pituitary LH (80/552) for the specific LH assay. In the assay for 
hCG the two monoclonal antibodies were directed against different antigenic 
determinants of hCG, to ensure the detection of the intact hCG molecule 
without crossreaction of its subunits. The assay had a crossreactivity for LH of 
less than 0.5%. The detection limit was 0.5 U/L, the intra-assay variation less 
than 1 0 % , the inter-assay variation less than 1 1 % , the standards were cali­
brated against the WHO 3rd International Standard of human chorionic gonado­
tropin for immunoassay (75/537). LH bioactivity was measured by an in-vitro 
bioassay based on the induction by LH of progesterone production in mouse 
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Leydig tumour cells (Dahl et al., 1993). E2 and Ρ concentrations were measured 
by RI As as previously described (Thomas et al., 1977). 
Results 
The absolute amounts of FSH, LH, specific LH and hCG in ampoules from the 
batches used for the study were determined by immunoassays (DELFIAs). In an 
ampoule of Humegon 35.6 IU FSH was present, in an ampoule of Pergonal 36.2 
IU. The amount of total LH was 16.5 IU and 17.7 IU in a Humegon and a 
Pergonal ampoule, respectively; the amount of specific LH was 8.7 IU and 7.8 
IU in a Humegon and a Pergonal ampoule. In both preparations hCG was 
present: 13.6 IU in an ampoule of Humegon and 11.5 IU in a Pergonal ampoule. 
In all women adequate pituitary suppression was reached fourteen days after 
the triptorelin injection, i.e. the difference in FSH and LH concentrations be­
tween day 13 and day 14 was not greater than the intra-assay variation and the 
serum E2 concentration did not exceed 200 pmol/L. FSH, LH, specific LH and 
hCG concentrations reached baseline values within one week after the first hMG 
injection and the order in which the injections were given did not influence the 
results. 
Calculated AUC and terminal half-life of FSH, LH, bioactive LH and hCG con­
centrations after injection of each preparation are listed in Table 1. The AUC and 
half-life of specific LH could not be determined, therefore the AUD was cal­
culated. Mean serum concentrations of FSH, specific LH and hCG after injection 
of either Humegon or Pergonal are shown in Figures 1, 2 and 3. Figure 4 shows 
immunologic LH and bioactive LH concentrations after injection of each prepa­
ration. Five to eight weeks after the triptorelin injection, FSH, LH and E2 con­
centrations started to increase to pretreatment values. 
Humegon and Pergonal appeared to be bioequivalent with respect to FSH 
immunoreactivity. Bioequivalence could not be proven for total and specific LH 
immunoreactivity due to the small number of subjects, but the preparations 
were bioequivalent with respect to hCG immunoactivity. 
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Figure 4. Mean baseline-corrected serum LH concentrations after a single intrave-
nous injection of 225 IU of Humegon (A) and Pergonal (B) during trip-
torelin administration in nine healthy female volunteers, measured by 
DELFIA and by in-vitro bioassay. 
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Table 1. The area under curve (AUC) and terminal half-life of serum FSH, total LH, 
bioactive LH and hCG, and the area under data (AUD) of specific LH, after 
a single intravenous injection of 225 IU of Humegon and Pergonal in nine 
healthy women. A two-compartment model was applied. 
FSH 
total LH 
specific LH 
bioactive LH 
hCG 
AUC (IU.h/l) 
half-life (h) 
AUC (lU.hfl) 
half-life (h) 
AUD (IU.h/l) 
AUC (IU.h/l) 
half-life (h) 
AUC (IU.h/l) 
half-life (h) 
Humegon 
431.5 ± 66.5 
22.20 ± 8.86 
127.1 ± 33.5 
19.93 ± 10.76 
17.50 ± 4.90 
376.1 ± 127.1 
21.28 ± 11.18 
153.7 ± 26.9 
14.80 ± 3.46 
Pergonal 
402.6 ± 59.9 
21.33 ± 5.05 
106.3 ± 25.5 
17.07 ± 8.40 
21.79 ± 5.31 
346.6 ± 191.1 
19.77 ± 8.90 
134.1 ± 28.1 
12.11 ± 4.54 
Discussion 
The preparations which were used in the study, Humegon and Pergonal, contain 
FSH, LH and hCG. Each ampoule contains approximately 75 IU FSH and 75 IU 
LH, as determined by in-vivo bioassays. In serum usually FSH and LH immuno-
reactivity is determined, instead of bioactivity. Since immunoreactivity and 
bioactivity are not completely comparable, we measured the amount of ¡m-
munoreactive FSH, LH, specific LH and hCG in the Humegon and Pergonal 
ampoules used for the study. The absolute amount of each hormone present in 
an ampoule from each batch, measured by immunoassays, was almost similar in 
the two preparations. 
Intramuscular administration of the long-acting GnRH-agonist Decapeptyl ap-
peared to be effective in suppressing pituitary and ovarian function from two 
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weeks until five to eight weeks after administration. Endogenous FSH and LH 
levels were sufficiently suppressed to measure exogenously administered FSH 
and LH. However, the suppression was not complete and baseline values were 
not below the detection limit of the assay. Therefore a correction for baseline 
values was carried out. 
The AUC and half-life of FSH was very similar for both preparations and 
Humegon and Pergonal appeared to be bioequivalent with respect to FSH 
immunoreactivity. Most authors who reported on pharmacokinetics also used a 
two-compartment model with a fast and a slow component of the disappearance 
curve of FSH. Amin and Hunter (1970) administered pituitary FSH intravenously 
in men, and measured a mean half-life of approximately 30 minutes. Diczfalusy 
and Harlin (1988) described FSH concentrations after i.v. administration of 150 
IU of Humegon, Pergonal and Metrodin in women with normal pituitary function. 
The terminal half-life of FSH was 1 1 , 10 and 7.3 hours respectively. We 
calculated a longer half-life of the slow component of the disappearance curve. 
In both previous studies RIAs were applied for the determination of FSH con-
centrations, wi th lower sensitivity than the assay we used. Therefore we were 
able to measure exogenous FSH up to 144 hours after the hMG administration. 
Since the estimation of the terminal half-life is made from the terminal part of 
the disappearance curve (log-scale), and the slope of the curve tends to de-
crease in time, it can be expected that applying a more sensitive assay leads to 
calculation of a longer half-life. This is confirmed by the results of a study by 
Jockenhövel et al. (1990). They also used a sensitive assay (IRMA) for deter-
mination of FSH concentrations after a single i.m. injection of 150 or 450 IU 
urinary FSH in pituitary down-regulated men. A one-compartment model was 
used for calculation of pharmacokinetic parameters. They estimated a long half-
life of 24.6 (150 IU FSH) and 36.2 hours (450 IU FSH). Urban et al. (1991) 
administered 250 IU purified urinary FSH (Metrodin) intravenously in hypogona-
dotrophic men. They measured FSH concentrations by RIA, IRMA and in-vitro 
bioassay and found no significant differences among the three assays. Applying 
a two-compartment model, they calculated a terminal half-life of approximately 
10 hours. These results seem to contradict our theory about different assay 
sensitivity leading to different half-life estimations. However, Urban et al. only 
measured FSH concentrations up to 30 hours after injection. As can be seen in 
Figure 1, the slope of our disappearance curve is significantly lower in the time 
period from 30 to 144 hours after injection. If that period is used for calculation 
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of the terminal half-life, as we did, the half-life will be longer than when the 
values before 30 hours after injection are used for calculation. Because the 
introduction of sensitive and specific assays appears to have an influence on 
pharmacokinetic results, it would be interesting to compare immunoreactive FSH 
levels with bioactive FSH levels as determined by in-vitro bioassays, and to 
investigate whether the bioactive to immunoreactive ratio changes in time after 
the hMG or FSH administration. 
Serum LH concentrations were determined by an immunoassay which was not 
very specific and showed crossreaction with hCG, so both the LH and hCG 
component of the administered preparation were measured. A specific LH 
immunoassay and an hCG assay could differentiate between the two com-
ponents. For both preparations the immunoreactivity of total LH was much 
higher than that of specific LH, indicating that hCG was responsible for a large 
part of the LH immunoreactivity in each preparation. Bioactive serum LH levels, 
determined by the Leydig tumour cell assay, correlated well with immunoreac-
tive LH levels as measured by the nonspecific LH assay. 
Previous studies on LH pharmacokinetics described the disappearance of 
endogenous LH after hypophysectomy in two women (Yen et al., 1968) and the 
disappearance of pituitary LH after i.v. infusion in men (Kjeld eta/., 1976), using 
RIAs. Yen et al. calculated a slow component half-life of approximately 4 hours, 
Kjeld et al. found a mean half-life of 2.3 hours. Diczfalusy and Harlin (1988) 
measured serum LH levels after i.v. administration of 150 IU of Humegon and 
Pergonal in women with normal pituitary function. Because of the interference 
of endogenous LH, they could not estimate the half-life of exogenously ad-
ministered LH. A calculation of the half-life of LH could only be made in a 
hypophysectomized woman. The LH level was measured by an in-vitro bioassay. 
The fast component half-life was 1.2 and 1.3 hours for Humegon and Pergonal, 
respectively, the slow component half-life was 3.3 hours for both preparations. 
We also measured bioactive LH, applying an other in-vitro bioassay, but found a 
much longer half-life of the slow component. 
More studies have been performed on hCG pharmacokinetics. Wide et al. (1968) 
administered 94000 to 131000 IU hCG intravenously in three amenorrhoeic 
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women. They estimated a mean half-life of 8 hours using a one-compartment 
model. Rizkallah et al. (1969) administered 10000 IU hCG intravenously in three 
male and three female subjects. They described a two-component disappearance 
curve with a half-life of 5.6 hours for the fast component and a half-life of 23.9 
hours for the slow component in the female subjects. We calculated a shorter 
slow component half-life. The assay we applied was a DELFIA detecting only 
the intact hCG molecule without crossreaction with the a- and ß-subunits. The 
other authors applied less specific assays. Possibly, in the study by Rizkallah et 
al., dissociation of the intact hCG molecule in its subunits was responsible for 
longer hCG immunoactivity, and thus for a longer half-life. 
In conclusion, triptorelin administration suppressed pituitary and ovarian function 
sufficiently to study pharmacokinetic parameters of hMG after a single i.v. 
injection. The two hMG preparations which were studied, were bioequivalent 
with respect to FSH and hCG immunoreactivity. Bioequivalence could not be 
proven for LH immuno- and bioactivity. HCG is responsible for a considerable 
part of LH bioactivity in hMG. 
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Hormonal serum profiles and follicular development 
after intramuscular and pulsatile intravenous 
administration of human menopausal gonadotrophin 
U.M. Duijkers, J.M.G. Hollanders, W.N.P. Willemsen, C.M.G. Thomas, 
G.F. Borm, H.M. Vemer 
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Abstract 
A study was performed to compare in a randomized way the effect of pulsatile 
intravenous (ι v.) and intramuscular (i.m.) human menopausal gonadotrophm (hMG) 
administration on hormonal serum profiles and follicular development in in vitro 
fertilization (IVF). 
Fourteen IVF patients participated in the study, aged between 20 and 40 years, with a 
normal endocrine profile, no hormonal medication used for at least three months 
previously, no endometriosis, both ovaries present, and a normal male factor. Seven 
patients were treated with i.m. hMG at a daily dose of 150 IU, and 7 patients with 
pulsatile i.v. hMG at a daily dose of 112 5 IU, in both cases in combination with 
buserelin. Ultrasonography was performed every other day during the stimulation phase 
and blood samples were collected once daily up to five times a day during the entire 
IVF cycle. Serum concentrations of follicle-stimulating hormone, luteinizing hormone, 
17ß-oestradiol, progesterone and human chorionic gonadotrophm were determined. 
There were no differences in hormonal profiles between the two groups. The numbers 
of retrieved oocytes, fertilization rates and mean embryo quality were identical in this 
study, as was follicular growth 
In conclusion, in the present randomized study no differences were observed in 
hormonal levels or follicular development after ι m. and pulsatile i.v. hMG treatment. 
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Introduction 
Human menopausal gonadotrophs (hMG) has been used for almost thirty years 
to stimulate ovarian follicular growth. Urine-derived hMG preparations comprise 
follicle-stimulating hormone (FSH), luteinizing hormone (LH) and human chorio-
nic gonadotroph^ (hCG), and are usually administered once daily by intramus-
cular (i.m.) injection. The first reports on pulsatile intravenous (i.v.) ad-
ministration of hMG were by Afnan et al. (1984) and Ho Yuen et al. (1984). By 
this route of administration, pulsatile gonadotrophin release by the pituitary 
gland is mimicked more closely than when the i.m. route is used. Later, other 
authors compared i.m. and pulsatile i.v. administration of hMG in ovulation 
induction cycles in women with refractory anovulation (Ho Yuen et al., 1989) 
and in in vitro fertilization (IVF) cycles, in low-responder patients and women 
with normal ovarian function (Edelstein et al., 1990, Prak et al., 1992). Prak et 
al. (1992) reported higher pregnancy rates after pulsatile i.v. than after i.m. 
hMG treatment. However, as with all the investigations mentioned, their study 
did not have a randomized design, meaning that the higher pregnancy rates 
could have been due to pre-existing differences between the study groups. 
We decided to perform a randomized study to investigate whether the previous-
ly reported superior results obtained with pulsatile i.v. hMG treatment as against 
routine i.m. treatment could be confirmed. The study was carried out in a well-
defined group of women undergoing IVF treatment who had normal endocrine 
profiles. Administration of hMG was combined with gonadotrophin-releasing-
hormone agonist (GnRHa) treatment. We evaluated the effects of i.m. and 
pulsatile i.v. hMG treatment on hormonal profiles in serum and on follicular 
development. Both hormonal profiles and follicular growth were monitored very 
closely to detect any differences between the two methods which might explain 
the possible increase in pregnancy rates. During the initial treatment days, 
multiple samples were taken to compare the increase of FSH and E2 con-
centrations. In addition, the numbers of retrieved oocytes, fertilization rates and 
mean embryo quality were assessed in both groups. 
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Materials and methods 
Patients 
Fourteen women undergoing IVF treatment for tubal pathology or unexplained 
infertility participated in the present study. The inclusion criteria were: age 
between 20 and 40 years, normal endocrine serum profile in the early follicular 
phase of the cycle (FSH concentration below 8 IU/1, LH/FSH ratio less than 3, 
testosterone concentration below 2.5 nmol/l, prolactin concentration below 700 
mlU/l and thyroxine concentration between 58 and 148 nmol/l), no hormonal 
medication for at least three months prior to the study, no endometriosis obser­
ved on laparoscopy, both ovaries present, and a normal male factor (either a 
normal semen analysis, i.e. at least 5 0 % motile sperm, motility grade at least 
fairly good i.e. score 4 on a scale from 1 to 6, at least 6 0 % morphologically 
normal sperm and absence of antisperm antibodies as confirmed by the direct 
immunobead test (WHO, 1992), or a fertilization rate of at least 5 0 % if the 
patient had had IVF before). 
The study was approved by the hospital's Ethical Committee and all the women 
gave their informed consent. The patients were randomly allocated to one of 
two groups. Seven patients received hMG (Humegon, Organon International BV, 
Oss, Netherlands) via the i.m. route (Group A). The other 7 patients received 
hMG via the pulsatile i.v. route (Group B). 
The indication for IVF in Group A was tubal infertility in 3 patients and unex­
plained infertility in 4 patients. Two patients had had IVF treatment previously. 
In Group В the indication for IVF was also tubal infertility in 3 patients and 
unexplained infertility in 4 patients. Three patients had had IVF treatment 
previously. The groups were comparable with respect to mean age, weight and 
early follicular FSH concentrations (33 years, 66 kg and 5.6 IU/L in group A, 30 
years, 61 kg, and 7.2 IU/L in group B). 
Induction protocol 
Intranasal administration of the GnRHa buserelin (Suprefact, Hoechst A.G., 
Frankfurt, Germany) was started on day 21 of the menstrual cycle, at a dose of 
300 μ§ three times a day. On the tenth day of buserelin administration, transva-
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ginal ultrasonography was performed to exclude the presence of ovarian cysts. 
Serum 17ß-oestradiol (E2) concentration was determined the same day by time-
resolved fluoroimmunoassay (Delfia, Wallac Oy, Turku, Finland). If the serum E2 
concentration was below 500 pmol/l, administration of hMG was started the 
next day (day 3 of the IVF cycle) and the buserelin medication was continued. If 
the E2 level remained higher than 500 pmol/l, the administration of buserelin 
was continued but hMG administration was postponed until the serum E2 
concentration had fallen below 500 pmol/l (determined every two or three 
days). 
Humegon was given either by i.m. administration between 5.00 and 6.00 p.m. 
at a fixed dose of two ampoules (150 IU) daily, or by pulsatile i.v. admini-
stration at a fixed total daily dose of 1.5 ampoules (112.5 IU) with a pulse 
interval of 90 minutes. The lower daily dose for the i.v. route as compared with 
the i.m. route was based on the work of Ho Yuen et al. (1984), who had 
described an approximately 4 0 % reduction in the dose. We reduced the daily 
dose for the i.v. route to 1.5 ampoules hMG per day. An i.v. catheter was 
inserted into a forearm or upper arm vein. Six ampoules of hMG were diluted in 
2.6 ml prednisolone-heparin solution and 40 μ\ were administered in each pulse 
via a computerized pump (MiniMed Infusion Pump 404-SP, Minimed Tech­
nologies, Sylmar, CA, USA; Microdose Pump MRS 5, Disetronic AC, Burgdorf, 
Germany). The pump was refilled with fresh hMG solution every four days. 
Eleven patients were treated with Humegon from the same batch, while the 
other 3 patients were treated with Humegon from another batch with similar 
FSH and LH in vivo bioactivity (85 IU FSH and 81 IU LH, 79 IU FSH and 68 IU 
LH respectively). 
The administration of gonadotrophins was discontinued as soon as at least three 
large follicles were present (diameter à 15 mm), one of which with a diameter 
> 20 mm, and the E2 concentration was higher than 1000 pmol/l per large 
follicle. On the day these criteria were satisfied no hMG was administered i.m., 
and the infusion pump for i.v. hMG administration was stopped immediately 
before the i.m. hCG injection of 10,000 IU human chorionic gonadotrophin 
(hCG, Pregnyl, Organon International BV, Oss, Netherlands) at 11.00 or 12.00 
p.m. Buserelin was administered until 12.00 p.m. that night. 
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Transvaginal ultrasound-guided oocyte retrieval was performed 35 hours after 
the hCG injection. After oocyte retrieval 5000 IU hCG were injected i.m., 
followed by 1500 IU hCG i.m. between 10.00 and 12.00 a.m. every other day 
until day 10 after follicle aspiration. Two batches of both hCG 5000 IU and hCG 
1500 IU were used for all patients. The retrieved oocytes were counted and 
their quality (immature, mature, postmature, luteinized) was scored. The number 
and quality of the embryos were scored also, on a scale from 1 (bad) to 5 
(good). Embryo transfer was performed on day 3 after oocyte retrieval. 
Blood sampling 
Blood samples were collected between 8.00 and 10.00 a.m. on days 20, 22, 
24, 27 and 30 of the cycle prior to the IVF cycle (before and during buserelin 
treatment). If the hypo-oestrogenic state had not yet been reached, further 
samples were obtained every two or three days thereafter until the serum E2 
concentration was lower than 500 pmol/l. On the first day of hMG admini-
stration (day 3 of the IVF cycle) blood samples were taken immediately before 
the first i.m. injection (at 5.00 p.m.) or before the insertion of the i.v. catheter 
(between 2.00 and 5.00 p.m.), and also at 8.00 and 11.00 p.m. The next day, 
blood samples were drawn at 8.00 and 12.00 a.m., and at 5.00, 8.00 and 11 
p.m. On day 5 blood was collected at 8.00 a.m. and 5.00 p.m. Thereafter, 
blood samples were taken once daily between 8.00 and 10.00 a.m. for the rest 
of the IVF cycle until the day of the pregnancy test or the first day of the next 
period. The blood was allowed to clot at room temperature; it was then centri-
fuged at 1000xg for 5 minutes and the serum samples were stored at -20°C 
until assayed. 
Ultrasound 
Vaginal ultrasound examinations were performed on day 20 of the previous 
cycle, on day 10 of buserelin administration and subsequently every other day 
from day 5 of the IVF cycle until the day of hCG administration. 
Hormonal assays 
Concentrations of FSH, LH and E2 were determined in all serum samples. 
Progesterone (P) concentrations were determined during the luteal phase of the 
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previous cycle, i.e. the cycle before the actual treatment, on day 7 of the 
stimulation phase and daily from day 12 of the stimulation phase onwards. 
Serum hCG concentrations were determined once daily during the treatment 
cycle. FSH and LH concentrations were determined by immunoradiometric 
assays, which have been described previously (Kremer et al., 1991). E2 and Ρ 
concentrations were determined by radioimmunoassays (Thomas et al., 1977). 
Human chorionic gonadotrophin concentrations were measured by an immuno 
enzymetric assay specific for intact hCG (Tandem-Ε hCG, Hybritech Europe 
S.A., Liège, Belgium). 
Statistics 
Concentrations below the detection limit were assigned the minimum detectable 
concentration for the assay. Differences between the groups were evaluated 
using Wilcoxon's rank sum test. In order to evaluate hormonal profiles, a limited 
number of characteristics were selected, viz. the increment in serum FSH and E2 
concentrations during the stimulation phase, plateau FSH concentrations and 
peak E2 concentrations in the stimulation phase. 
Results 
The serum FSH, LH and E2 concentrations in the two groups are shown in 
Figures 1, 2 and 3. One cycle in Group В was cancelled on cycle day 16 
because of poor ovarian response. On ultrasonography no follicular growth was 
seen and serum E2 concentrations did not exceed 500 pmol/l. In another cycle in 
Group В none of the retrieved oocytes were fertilized, despite good semen 
motility. The results for the luteal phase of the previous cycle and for the 
stimulation phase in Figures 1, 2 and 3 include the values for the cancelled 
cycle and the cycle without fertilization. The results for the luteal phase of the 
IVF cycle do not include the values of the said two cycles. 
There were no significant differences between the groups treated by i.m. and 
pulsatile i.v. hMG administration (Groups A and В respectively). The rates of 
increase in serum FSH and E2 concentrations during the initial days of hMG 
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Median serum FSH concentrations (10th and 90th percentiles) during IVF 
cycles in 7 patients treated with hMG i.m. (A) and 7 patients treated with 
pulsatile i.v. hMG (Β). Ρ is the day of oocyte retrieval. FSH concentrati­
ons during the initial days of hMG treatment are shown in the inset. 
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Figure 2 Median serum LH concentrations (10th and 90th percentiles) during IVF 
cycles in 7 patients treated with hMG i.m. (A) and 7 patients treated with 
pulsatile i.v. hMG (Θ). 
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administration were similar (see insets in Figures 1 and 3). The plateau FSH 
concentration, defined as the mean concentration from day 5 to day 10, was 
8.9 IU/I in Group A and 9.8 IU/I in Group B. The median values of the peak E2 
concentrations on the day before oocyte retrieval were 17000 pmol/l in Group A 
and 15500 pmol/l in Group B. 
Serum Ρ concentrations in the luteal phase of the previous cycle reached 
maximum values on day 24. The median value in Group A was 78 nmol/l (tenth 
percentile (p10) 53, ninetieth percentile (pgo) 110 nmol/l), and in Group В it was 
58 nmol/l (p 1 0 36, p 9 0 110 nmol/l). During the stimulation phase of the IVF 
cycle, progesterone concentrations were undetectably low, increasing just 
before or just after the hCG injection. During the luteal phase of the IVF cycle 
high progesterone concentrations were observed, reaching maximum values 9 
days after oocyte retrieval. The maximum progesterone concentration in the 
nonpregnant patients in Group A was 450 nmol/l (median value, p 1 0 230, p 9 0 
710 nmol/l), and in Group В it was 580 nmol/l (p,0 490, p 9 0 1600 nmol/l). There 
were no significant differences between the groups. 
The administration of hMG, which contained a certain amount of hCG, did 
hardly influence serum hCG levels. In the follicular phase of the IVF cycle serum 
hCG concentrations remained below the detection limit of the assay (2.5 IU/I), 
only slightly increasing on the last day before hCG administration (median value 
2.5 IU/I in Group A and 3 IU/L in Group B). One patient in Group В had raised 
hCG levels throughout the follicular phase (3.7 to 8.4 IU/I), even before the 
start of hMG administration. When other assays for hCG were applied for these 
serum samples (another sandwich-assay and a radioimmunoassay), hCG 
concentrations were below the detection limit of the assay (2.0 IU/L and 1.0 
ng/mL, respectively). The increased hCG values will therefore not be of clinical 
relevance. After the administration of 10000 IU hCG serum hCG levels in­
creased. The maximum serum hCG concentration was reached on the first day 
after oocyte retrieval (the median value in Group A was 320 IU/I (p 1 0 150, p 9 0 
460 IU/I), and in Group В it was 390 IU/I (p1 0 270, p 9 0 670 IU/I). Thereafter a 
gradual fall in hCG concentrations was observed. 
The median duration of the stimulation phase seemed shorter for Group В than 
for Group A (Table 1), but the difference was not statistically significant. The 
total number of ampoules used was lower for Group В than for Group A (105 
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Figure 3 Median serum E2 concentrations (10th and 90th percentiles) during IVF 
cycles in 7 patients treated with hMG i.m. (A) and 7 patients treated with 
pulsatile i.v. hMG (Β). Ρ is the day of oocyte retrieval. E2 concentrations 
during the initial days of hMG treatment are shown in the inset. In the 
luteal phase the results for 4 nonpregnant (solid line) and 3 pregnant 
patients (dotted line) patients are shown. 
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ampoules versus 158 ampoules) due to the lower daily dose. Table 1 shows 
median values of the numbers of follicles with a diameter greater than 15 mm at 
the last ultrasonography before oocyte retrieval, the numbers of retrieved 
oocytes, the fertilization rates and the mean embryo quality in the two groups. 
There were no significant differences between the groups. 
One patient in group В experienced leakage from the infusion pump system on 
day 13 of the stimulation phase of the cycle, leading to a drop in serum FSH 
concentrations from 12 to 4.9 IU/I. This problem was corrected within 24 hours 
and serum FSH concentrations then increased again. Serum E2 concentrations 
did not decrease during this leakage problem. None of the patients showed 
signs of phlebitis. Three patients in group A had a positive pregnancy test. One 
of the three had bleeding two days later and a second pregnancy test was 
negative. There were no pregnancies in Group B. 
Table 1. Cycle characteristics of 7 patients treated with i.m. hMG and 7 patients 
treated with pulsatile i.v. hMG, median values with 10th and 90th 
percentiles in parentheses 
hMG i.m. hMG i.v. 
Days of stimulation 
Number of large folliclesΊ 
Number of retrieved oocytes 
0/„2 Fertilization rate, % 
Mean embryo quality' 
12 (7-18) 
12(5-24) 
11 (2-17) 
76 (50-100) 
3.9 (3.0-5.0) 
9(9-17) 
12 (0-22) 
12 (7-17) 
76 (0-94) 
3.5 (2.4-4.4) 
1
 largest diameter ¿ 1 5 mm, as measured at the last ultrasound examination 
2
 six patients in the group treated with hMG i.v. 
3
 scale 1 (bad) to 5 (good), five patients in the group treated with hMG i.v. 
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Discussion 
Hormonal profiles in the serum of women undergoing IVF treatment were 
meticulously monitored in the present study. A large interindividual variation in 
hormonal concentrations was observed, but median values in the two groups 
did not show significant differences. The increase in FSH concentrations after 
the start of hMG treatment was comparable in the two groups, as was the 
plateau FSH level between days 5 and 10 of the stimulation phase. In addition, 
the increase In E2 concentrations during hMG administration and the peak E2 
concentrations were similar in the two groups. There were no differences 
between the groups as regards follicular growth, numbers of oocytes, fertili-
zation rates or embryo quality. This indicates that pulsatile i.v. hMG admini-
stration does not lead to better results than the routine i.m. hMG treatment. 
It could be argued that the absence of better results after pulsatile i.v. treatment 
was due to the lower daily dose in this group. This lower dose was based on 
the results of a previous study (Ho Yuen et al., 1984). However, the plateau 
FSH levels during hMG treatment were similar in the two groups, which means 
that the bioavailability of two ampoules of hMG administered i.m. is comparable 
to that of 1.5 ampoules administered i.v. 
Previous studies on pulsatile I.v. hMG treatment showed that the pulsatile i.v. 
administration route was possibly more beneficial. Moreover, in one of these 
studies a lower daily hMG dose was used for pulsatile I.v. treatment as com-
pared with i.m. treatment. The first reports of the successful induction of ovula-
tion by pulsatile i.v. hMG administration were by Afnan et at. (1984) and Ho 
Yuen et al. (1984). Ho Yuen and co-workers (1989) reported the results of 107 
pulsatile I.v. hMG treatment cycles in 30 women with refractory anovulation. 
Twelve women with polycystic ovary (PCO) syndrome had had previous i.m. 
treatment cycles. Retrospective comparison of the two treatment methods 
reveals that less hMG was needed in the i.v. treatment cycles than in the i.m. 
treatment cycles. 
Edelstein et al. (1990) performed a study involving 6 IVF patients with a low 
response to high-dose gonadotrophs administration (450 IU purified FSH daily). 
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They were treated with 450 IU FSH per day by pulsatile ¡.v. administration. 
Although the plateau FSH levels were significantly higher after i.v. than after 
i.m. treatment, the numbers of oocytes and fertilization rates did not improve 
after i.v. treatment. The authors concluded that pulsatile i.v. gonadotrophin 
treatment was not of major benefit for the stimulation of low-responder pa-
tients. 
Prak et al. (1992) gave hMG by pulsatile i.v. administration over 82 IVF cycles 
in women with tubal or unexplained infertility. They compared the results with 
those for 231 cycles in which hMG was administered i.m. The hMG therapy 
was combined with GnRH-agonist treatment. The dose of hMG was 4 0 % lower 
than that used in a previous cycle of i.m. treatment. The numbers of follicles 
and oocytes were similar in the two groups but the pregnancy rate was signi-
ficantly higher in the group treated i.v. than in the i.m. treatment group. The 
authors ascribed this higher pregnancy rate to improved oocyte quality and 
endometrial receptivity as a result of the more physiological method of ovarian 
stimulation. However, none of the previously published studies was well-
controlled and randomized. 
As stated above, the fact that the beneficial effect of pulsatile i.v. hMG ad-
ministration could not be confirmed in a randomized trial indicates that differen-
ces between study groups in previous investigations may explain the results. 
However, further randomized studies are needed in patients suffering from PCO 
syndrome and patients whose response was poor in previous cycles. 
The half-life of FSH, as present in hMG, is approximately 11 hours after i.v. 
administration (Diczfalusy and Harlin, 1988). Because of the long half-life, 
pulsatile hMG administration will result in a gradual accumulation of FSH in the 
circulation, instead of a pulsatile FSH pattern. In contrast to the pulsatile i.v. 
GnRH treatment, where because of the very short half-life of GnRH a clear 
pulsatile pattern is present (Handelsman et al., 1984), the individual hMG pulses 
will contribute very little to the high plateau FSH level. This is supported by our 
results during the initial treatment days, showing a gradual increase in FSH 
concentrations leading to a steady state level, with comparable patterns in the 
two groups. To investigate whether very small fluctuations in the plateau FSH 
level occur during pulsatile i.v. treatment, very frequent blood sampling is 
required. The long half-life of FSH and the similar patterns of serum FSH 
concentrations during the entire stimulation period explain why pulsatile i.v. 
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hMG treatment did not lead to better results. 
In conclusion, the results of the present study indicate that the effect of 
pulsatile i.v. hMG treatment is not superior to that of i.m. treatment in women 
with normal endocrine profiles. Moreover, the pulsatile ¡.v. treatment has 
practical disadvantages as compared with i.m. treatment, namely the vul-
nerability of the administration system, as illustrated by the leakage from the 
infusion system experienced by one of the patients. Inserting and refilling the 
infusion system are time-consuming procedures. Furthermore, there is the 
serious risk of flebitis and subsequent sepsis, complications which were seen 
during pulsatile i.v. GnRH treatment. The routine i.m. hMG treatment remains 
therefore preferable to pulsatile i.v. treatment. 
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Different follicle stimulating hormone / luteinizing 
hormone ratios for ovarian stimulation 
U.M. Duijkers, H.M. Vemer, J.M.G. Hollanders, W.N.P. Willemsen, 
L.A. Bastiaans, C.J.CM. Hamilton, C.M.G. Thomas, G.F. Borm 
Hum. Reprod. 8: 1387-1391, 1993* 
* Compared to the manuscript as published in the above mentioned journal, a correction of the 
median fertilization rate in the Metrodin group was made. 
Abstract 
The aim of the present study was to investigate whether reducing the amount of LH in 
gonadotrophic preparations impairs follicular growth in IVF cycles during suppression of 
endogenous LH levels. A selected group of 20 IVF patients was randomly divided into 
two groups. One group was treated with Normegon (FSH/LH 3:1), the other group with 
Metrodin (purified FSH), both during pituitary downregulation with buserelin. A fixed 
daily dose of 150 IU FSH ι.m. was given. Serum concentrations of FSH, LH, oestradiol 
and progesterone were determined frequently and serial ultrasound examinations were 
performed. 
Multiple follicular growth with concomitant rise of oestradiol levels was observed in all 
cycles. The duration of the stimulation phase was shorter in the group treated with 
Normegon than in the group treated with Metrodin. The number of follicles and oocytes 
was larger and the mean embryo quality was higher in the Normegon group but the 
differences did not reach statistical significance. No significant differences were found 
in hormonal values. In women with normal endocrine profiles lowering of the LH activity 
in gonadotrophic preparations during GnRH-agonist treatment results in adequate 
ovarian stimulation However, a preparation with some LH needed a shorter stimulation 
than a purified FSH preparation. Whether the other beneficial effects of Normegon also 
occur in a larger population needs further investigation. 
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To stimulate multiple follicular growth in in vitro fertilization (IVF) cycles, human 
menopausal gonadotrophin (hMG) is usually administered. Human menopausal 
gonadotrophin is derived from urine of postmenopausal women and is composed 
of equal amounts of follicle stimulating hormone (FSH) and luteinizing hormone 
(LH) activity as measured by in-vivo bioassays. 
For controlled ovarian hyperstimulation in women with a regular cycle probably 
less LH activity than FSH activity is necessary. In the follicular phase of a 
spontaneous menstrual cycle, serum LH levels are low while FSH levels are 
relatively high. Only a small amount of LH is necessary for follicular growth 
(Berger and Taymor, 1971, Edelstein et al., 1990). During intranasal buserelin 
therapy, the suppression of endogenous LH production is not complete and 
some LH is still detectable (Palermo et al., 1988). 
The aim of the present study was to evaluate whether reducing the amount of 
exogenous LH activity in the gonadotrophic preparation has an adverse effect on 
ovarian hyperstimulation. This effect was investigated in a selected group of 
women with normal endocrine profiles undergoing IVF-treatment, while the 
endogenous LH secretion was suppressed with intranasal administration of 
buserelin. We compared ovarian response after treatment with a gonadotrophic 
preparation containing FSH and LH in a ratio of 3:1 (as determined by in-vivo 
bioassay) with a preparation containing FSH and almost undetectable amounts 
of LH. The efficacy of ovarian stimulation was assessed by vaginal ultrasono-
graphy, hormonal profiles in serum and the number and quality of oocytes and 
embryos. 
Materials and methods 
Patients 
Twenty women undergoing IVF treatment participated in the present study. 
Inclusion criteria were: age between 20 and 40 years, a normal endocrine serum 
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profile (FSH, FSH/LH ratio, testosterone, prolactine and thyroxin), no hormonal 
medication during the three months prior to the study, no endometriosis 
observed on laparoscopy, both ovaries present, normal semen analysis (at least 
5 0 % motile sperm, motility grade at least fairly good, at least 6 0 % morpho­
logically normal sperm, negative mixed agglutination test) or more than 5 0 % of 
the oocytes fertilized in a previous IVF treatment. 
The patients were randomly allocated to one of two groups. Ten patients were 
treated with the preparation Normegon (Organon International BV, Oss, The 
Netherlands), containing 75 IU FSH and 25 IU LH per ampoule as determined by 
in-vivo bioassays (Steelman & Pohley assay and seminal vesicle weight test, 
respectively). The other ten patients were treated with Metrodin (Serono, 
Pharma-lmport B.V., Haarlem, The Netherlands) containing 75 IU FSH and less 
than 0.11 IU LH per ampoule. The indication for IVF in the group treated with 
Normegon was tubal infertility in three patients, unexplained Infertility in six 
patients and cervical hostility in one patient. Three patients had previous IVF 
treatments. In the group treated with Metrodin, the indication for IVF was tubal 
infertility in five patients and unexplained infertility in five patients. Two patients 
had previous IVF treatments. 
IVF protocol 
On the 21st day of the menstrual cycle, intranasal administration of buserelin 
(Suprefact, Hoechst A.G., Frankfurt, Germany), 300 μ§ three times per day, 
was started. On the tenth day of buserelin administration a transvaginal ultra­
sound examination was performed to exclude the presence of ovarian cysts. 
Serum E2 concentration was determined the same day by time-resolved fluoro-
immunoassay (DELFIA, Wallac Oy, Turku, Finland). If the serum E2 concentra­
tion was below 500 pmol/L, administration of gonadotrophins was started the 
next day (day 3 of the IVF cycle). The buserelin medication was continued. If 
the E2 level was still higher than 500 pmol/L, the administration of buserelin was 
continued and the administration of gonadotrophins was postponed until the 
serum E2 level was below 500 pmol/L. 
The gonadotrophins were administered intramuscularly (i.m.) daily between 5.00 
and 6.00 p.m. in a fixed dose of 150 IU FSH. Only one batch of each gonado­
trophs preparation was used for the study. The administration of gonado-
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trophins was discontinued as soon as at least three follicles were present with a 
diameter > 15 mm, one follicle with a diameter ä 20 mm and the E2 con-
centration was higher than 1000 pmol/L per large follicle ( ä 15 mm). Buserelin 
was administered until that night and 10,000 IU hCG (Pregnyl, Organon Inter-
national BV, Oss, The Netherlands) were injected i.m. at 11.00 or 12.00 p.m. 
Transvaginal ultrasound guided oocyte retrieval was performed 35 hours after 
the hCG injection. Within one hour after oocyte retrieval 5000 IU hCG were 
injected i.m., every other day afterwards 1500 IU hCG were injected i.m. 
between 10.00 and 12.00 a.m. until the 10th day after follicle aspiration. The 
same batch of hCG 5000 IU and the same batch of hCG 1500 IU were used for 
all patients. Embryo transfer was performed on the third day after oocyte 
retrieval. 
Study protocol 
Blood samples were collected between 8.00 and 10.00 a.m. on the tenth day of 
buserelin administration, and subsequently daily from day 4 of the IVF cycle 
onwards until the day of oocyte retrieval. Thereafter blood samples were taken 
every other day until the tenth day after oocyte retrieval. The blood was allowed 
to clot at room temperature. If the blood was not centrifuged within 3 hours 
after venous puncture, it was stored at 4°C for a maximum of 6 hours. The 
blood was centrifuged at 3500 rpm for 5 minutes. The sera were stored at 
-20°C until assayed. 
Vaginal ultrasound examinations were performed on the 10th day of buserelin 
administration and subsequently every other day from day 5 of the IVF cycle 
until the day of hCG administration. 
The retrieved oocytes were counted and their quality (immature, mature, 
postmature, luteinized) was scored. Also the number and the quality of fertilized 
oocytes were scored on a scale from 1 (bad) to 5 (good). 
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Figure 1 Serum FSH concentrations (median values and 10th and 90th percentiles) 
on the day before the start of gonadotrophin administration (day 2), on 
cycle days 4 to 11, on the two days before oocyte retrieval (Ρ-2, P-1) in 
10 patients treated with Normegon (A) and 10 patients treated with 
Metrodin (В); on the day of oocyte retrieval and the second, fourth, sixth, 
eighth, tenth day thereafter (Ρ, Ρ+ 2, Ρ+ 4, Ρ + 6, Ρ+ 8, Ρ + 10) ¡η 9 
patients in each group. 
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Concentrations of FSH, LH and E2 were determined in all serum samples, and 
progesterone (P) concentrations from day 9 of the stimulation phase onwards. 
FSH and LH concentrations were determined by immunoradiometric assays 
(IRMAs) which were previously described (Kremer et al., 1991). E2 and Ρ 
concentrations were determined by radioimmunoassays (RIAs) (Thomas et al., 
1977). 
Statistics 
Statistical analysis was performed using the two-sample Wilcoxon test (rank 
sum test). Concentrations below the detection limit were assigned the minimum 
detectable concentration of the assay. 
The study was approved by the Ethical Committee of the hospital. All women 
gave their informed consent. 
Results 
Serum FSH, LH, E2 and Ρ concentrations in both groups are presented in Figures 
1, 2, 3 and 4, respectively. The values on the X-axis were ranked from day 4 
through day 1 1 , and subsequently from the second day before oocyte retrieval 
until the 10th day after oocyte retrieval, in view of the varying duration of the 
follicular phase. Serum FSH concentrations (Figure 1) increased during the first 
three days of gonadotrophs treatment, then reached a plateau level which 
remained constant until administration of gonadotrophins was discontinued. The 
median plateau concentrations of FSH were almost identical in the two groups 
(7.3 U/L in the Normegon group, 8.2 U/L in the Metrodin group). Serum LH 
concentrations (Figure 2) remained low during the entire cycle. Serum E2 (Figure 
3) and Ρ (Figure 4) concentrations did not differ significantly between the two 
groups, although the peak E2 concentration in the stimulation phase was higher 
in the Normegon group than in the Metrodin group (9100 pmol/L vs 6400 
pmol/L). 
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Day 
Figure 2 Serum LH concentrations (median values and 10th and 90th percentiles) 
on the day before the start of gonadotrophin administration (day 2), on 
cycle days 4 to 11, on the two days before oocyte retrieval (P-2, P-1) in 
10 patients treated with Normegon (A) and 10 patients treated with 
Metrodin (В); on the day of oocyte retrieval and the second, fourth, sixth, 
eighth, tenth day thereafter (Ρ, Ρ+ 2, Ρ+ 4, Ρ+ 6, Ρ+ 8, Ρ + 10) in 9 
patients in each group. 
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Oestradiol (χ 1000 pmol/L) 
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Day 
Β 
Oestradiol (χ 1000 pmol/L) 
s β 7 β β 10 11 Ρ+2 Ρ+4 Ρ + β Ρ+β Ρ+10 
Day 
Figure 3 Serum Ε2 concentrations (median values and 10th and 90th percentiles) 
on the day before the start of gonadotropin administration (day 2), on 
cycle days 4 to 11, on the two days before oocyte retrieval (P-2, P-l) in 
10 patients treated with Normegon (A) and 10 patients treated with 
Metrodin (B); on the day of oocyte retrieval and the second, fourth, sixth, 
eighth, tenth day thereafter (Ρ, Ρ+ 2, Ρ+ 4, Ρ+ 6, Ρ+ 8, Ρ+10) in 9 
patients in each group. 
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Ρ (nmol/U) 
В 
Ρ (nmol/L) 
P-2 P+2 
day 
Figure 4 Serum Ρ concentrations (median values and 10th and 90th percentiles) on 
cycle days 9 to 11, on the two days before oocyte retrieval (P-2, P-1) in 
10 patients treated with Normegon (A) and 10 patients treated with 
Metrodin (В) and on the day of oocyte retrieval and the second, fourth, 
sixth, eighth, tenth day thereafter (P, P + 2, Ρ+ 4, Ρ+ 6, Ρ+ 8, P+10) in 9 
patients in each group. 
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Median values of the duration of the stimulation phase, the number of large 
follicles (diameter larger than 15 mm) as seen on the last ultrasound examina-
tion, the number of retrieved oocytes, fertilization rate and the mean quality of 
the embryos in each group are listed in Table 1. The duration of the stimulation 
phase was significantly shorter in the Normegon group than in the Metrodin 
group (p < 0.05), and therefore the total number of administered ampoules was 
lower. The number of large follicles and retrieved oocytes appeared higher in the 
Normegon group than in the Metrodin group, and the mean embryo quality was 
better, but the differences did not reach statistical significance in this study (p 
> 0.15). In the group treated with Normegon one pregnancy was achieved, in 
the group treated with Metrodin two pregnancies, one of which appeared to be 
a non-vital pregnancy at ultrasonography. One patient in the Normegon group 
became pregnant later after transfer of embryos which were cryopreserved 
during the study cycle. 
In two women, one in each group, the cycle had to be cancelled due to a sharp 
decline of serum E2. In two cycles, one in each group, none of the retrieved 
oocytes were fertilized for unknown reasons. 
Discussion 
Human menopausal gonadotrophin preparations are purified from urine of 
postmenopausal women and contain FSH and LH activities. Human chorionic 
gonadotrophin may be added to the preparation in order to reach an LH bioac-
tivity of 75 IU, as determined with the seminal vesicle weight test (Vemer and 
Sanders, 1989). To obtain adequate follicular growth with corresponding serum 
E2 levels, a certain amount of LH activity has to be present (Berger and Taymor, 
1971, Schoot et al., 1992). Luteinizing hormone stimulates theca cell produc-
tion of androgens which are aromatised to oestrogens in the granulosa cells. 
The amount of LH activity in the routinely used gonadotrophic preparations 
(Humegon and Pergonal), however, is higher than necessary for an adequate 
ovarian stimulation in women with a normal menstrual cycle. 
Jacobson and Marshall (1969) performed a study in oligo- and anovulatory 
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Table 1. Cycle characteristics of 10 patients treated with Normegon and 10 
patients treated with Metrodin. Median values are presented, with the 
range in parentheses. 
Normegon Metrodin 
days of stimulation 8 (7-10)' 9 (9-15)' 
number of large follicles" 8.5 (4-22) 6 (3-18) 
number of retrieved oocytes 13(4-23) 8(4-11) 
fertilization rate, % 63(0-100) 67(0-100) 
mean embryo quality*'* 4.9 (2.1-5) 3.9 (1.7-5) 
* ρ < 0.05 
" largest diameter ¿ 1 5 mm, as seen at the last ultrasound examination before oocyte 
retrieval 
* " scale 1 (bad) to 5 (good) 
women, comparing treatment with gonadotrophic preparations containing 
different FSH/LH ratios (0.14, 0.90 and 3.0, respectively). They observed no 
ovulations after treatment with the preparation containing the highest FSH/LH 
ratio (3.0), compared to a 67% ovulation rate using the other preparations. 
Later, other studies comparing treatment with hMG and purified FSH were 
performed in patients with the polycystic ovary syndrome (Venturoli et al., 
1984, McFaul et al., 1990, Larsen et al., 1990, Tanbo et al., 1990). Treatment 
with both preparations resulted in adequate ovarian stimulation, without 
apparent differences. Török et al. (1991) compared purified FSH with hMG 
treatment in low responders. There was no difference in ovarian response. 
Russell et al. (1986) performed a (non-randomized) study in women with tubal 
pathology comparing treatment with 150 IL) FSH daily and 225 IU hMG daily, 
also observing no difference in ovarian response. 
Most of these studies were performed in groups of women with endocrine 
abnormalities with regard to FSH and LH levels. Therefore, these studies were 
different from our experiment, in the sense that our study group consisted of 
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women with normal endocrine profiles, who were treated with the GnRH-agonist 
buserelin. The endogenous LH levels are supposed to be lower in this group of 
patients than in PCO patients and even more suppressed by buserelin treatment. 
Edelstein et al. (1990) performed a similar study, comparing h M G and purified 
FSH treatment in an unselected group of women during leuprolide admini­
stration. The dosage of hMG or FSH was adjusted according to the individual 
response. No significant differences were observed in the number of oocytes, 
fertilization rate or E2 levels. In the present study strict selection criteria were 
used to minimize other factors possibly influencing the effect of ovarian stimu­
lation treatment. In order to make a better comparison a fixed dose of gonado­
t r o p i n s (150 IU FSH daily) was used. 
Median serum FSH concentrations in the stimulation phase of the cycles of 
either groups were similar, indicating comparable bioavailability of FSH in both 
preparations. The stimulatory effect of FSH on the ovaries is likely to be similar. 
Serum LH concentrations remained low during the follicular and luteal phase. 
Apparently, the administration of LH in Normegon does not result in a measu­
rable increase in immuno-active serum LH levels with the LH-IRMA employed, 
probably because of the short half-life of LH (Yen et al., 1968). 
In both groups of patients follicular growth was seen by ultrasound examination, 
and an adequate median number of oocytes was retrieved (13 and 8, respec­
tively). E2 production by the follicles and E2 and Ρ production by the corpora 
lutea were comparable in the two groups. The number of follicles and oocytes 
and the peak E2 concentration were somewhat higher in the Normegon group 
than in the Metrodin group, but the differences did not reach statistical signifi­
cance in this study. A similar conclusion can be drawn from the embryo quality. 
When some LH was present in the preparation the duration of the stimulation 
was shorter, and therefore a lower total number of ampoules was administered, 
reducing the cost of the treatment. 
As a conclusion, in a group of women with a normal endocrine profile lowering 
of the LH activity in hMG preparations during GnRH-agonist treatment does still 
result in ovarian stimulation. However, our study also indicates that a certain 
amount of exogenous LH has the advantage of a higher number of oocytes and 
111 
better embryo quality. Clinical research to test this hypothesis further is needed. 
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Chapter 7 
A comparison of recombinant human follicle-
stimulating hormone (Puregon) and human 
menopausal gonadotrophin in in vitro fertilization 
cycles 
U.M. Duijkers, J.M.G. Hollanders, C.J.CM. Hamilton, C.M.G. Thomas, 
H.J. Out, H.J.T. Coelingh Bennink, H.M. Vemer 
Abstract 
The effect of recombinant human follicle-stimulating hormone (recFSH, Puregon) admi-
nistration on follicular development and hormonal profiles was studied in in vitro 
fertilization (IVF) cycles. RecFSH was compared with human menopausal gonadotrophin 
(hMG) treatment. Both the intramuscular (i.m.) and subcutaneous (s.c.) administration 
route were applied for recFSH, and the efficacy and local tolerance were compared. 
Twenty IVF patients were included in the study: aged between 20 and 40, having a 
normal endocrine profile, both ovaries present, no endometriosis, normal body weight, 
and without male subfertility. Seven patients were treated with hMG (Humegon) i.m., 
six with Puregon i.m. In seven patients Puregon was administered s.c. The fixed daily 
dose was 150 IU. In all groups gonadotrophins were combined with buserelin treat-
ment. During the stimulation phase, daily blood samples were taken to determine 
follicle-stimulating hormone (FSH), luteinizing hormone, oestradiol (E2) and progesterone 
concentrations, and vaginal ultrasonography was performed at least every other day. 
Blood samples were also taken on the 2nd, 4th, 6th, 8th and 10th day after ovum pick-
up. 
There were no significant differences between i.m. hMG and recFSH treatment cycles, 
although the numbers of follicles, oocytes and E2 concentrations tended to be higher 
after recFSH treatment. Subcutaneous recFSH administration resulted in higher FSH 
concentrations than after intramuscular injection, but the numbers of follicles and 
oocytes were not different. S.c. injections of recFSH were well tolerated. 
In conclusion, RecFSH was as effective as hMG for ovarian stimulation treatment, even 
during pituitary suppression with buserelin. Subcutaneous recFSH administration was 
well tolerated and effective. 
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The production of human menopausal gonadotrophs (hMG) requires the 
collection of large amounts of urine. The active substance in urine-derived 
follicle-stimulating hormone (FSH) preparations has a limited biochemical purity. 
In search for other sources of FSH, the development of recombinant FSH 
(recFSH) was started. Recombinant FSH was produced by Chinese hamster 
ovary cells, transfected with the human FSH subunit genes (Van Wezenbeek et 
al., 1990). It appeared to have comparable aminoacid and carbohydrate com-
position, and similar biochemical and biological properties as natural FSH, inclu-
ding urinary FSH (De Boer and Mannaerts, 1990, Hard et al., 1990, Mannaerts 
et al., 1993). Clinical studies with recFSH (Puregon) have shown that the 
pharmacokinetic profile is comparable to that of natural FSH (Mannaerts et al., 
1993). In 1993 the first pregnancy after ovarian stimulation with recFSH was 
reported (Devroey et al., 1993). Randomized clinical studies were started to 
investigate the safety and efficacy of Puregon in in vitro fertilization (IVF) 
cycles. 
Although a small amount of luteinizing hormone (LH) appeared to be necessary 
for adequate ovarian stimulation with corresponding high serum E2 con-
centrations (Schoot et al., 1994), previous studies showed that the required 
amount of LH for adequate ovarian stimulation was quite low. Treatment with 
purified urinary FSH, containing a very small amount of exogenous LH, was as 
effective as preparations containing more LH activity, even during pituitary 
suppression by a gonadotrophin-releasing hormone agonist (GnRHa) (Duijkers et 
al., 1993). Puregon is a gonadotrophic preparation completely devoid of LH. 
Devroey et al. (1994) showed that during pituitary suppression with GnRHa, 
endogenous LH levels were sufficient for adequate ovarian stimulation with 
Puregon. In the present randomized study the efficacy of this preparation was 
compared with the standard hMG treatment. Only patients wi th normal en-
docrine profiles, who were supposed to respond "normally" to the medication 
were included in the study. A fixed dosing scheme of two ampoules of recFSH 
or hMG was used, because adjustment of the dosage during the treatment 
could mask differences in the ovarian response. 
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Gonadotrophic preparations are usually administered by the intramuscular (i.m.) 
route. I.m. injections usually have to be given by trained personnel and can be 
inconvenient or painful. The subcutaneous (s.c.) administration route has a 
number of advantages over the i.m. route: selfadministration is more feasible, 
and probably less painful. In the present study both administration routes were 
applied for Puregon, and the efficacy and local tolerance were compared. 
Materials and m e t h o d s 
Patients 
Twenty IVF patients participated in the study. Inclusion criteria were: age 
between 20 and 40 years, normal serum endocrine profile in the early follicular 
phase of the cycle (FSH concentration below 8 IU/L, LH/FSH ratio less than 3, 
testosterone concentration below 2.5 nmol/L, prolactin concentration below 
700 mlU/L, and thyroxin concentration between 58 and 148 nmol/L), both ova-
ries present, body weight between 80 and 130% of the ¡deal body weight 
(according to the Metropolitan Height and Weight Tables), and no male subfer-
tility (more than 20x10e sperm/mL, at least 30% motile sperm, motility grade at 
least fairly good, at least 4 0 % morphologically normal sperm, absence of sperm 
antibodies as confirmed with the direct immunobead test; or a fertilization rate 
of at least 50% if the patient had IVF before). Exclusion criteria were: treatment 
with hormonal medication in the two cycles preceding the IVF cycle, endome-
triosis observed on laparoscopy, chronic cardiovascular, hepatic, renal or 
pulmonary disease, and abuse of alcohol or drugs. All patients willing to 
participate underwent a general physical and gynaecological examination, 
cervical smear and a vaginal ultrasound examination. Routine blood bio-
chemistry, haematology and urinanalysis were done, and blood was taken for 
determination of anti-human FSH-antibodies. Blood and urine tests were 
repeated after completion of the study. 
The study was approved by the Ethical Committee of the hospital. All women 
gave their written informed consent. The patients were randomly assigned to 
one of three groups. Seven patients were treated with hMG i.m. (Humegon, NV 
Organon, Oss, The Netherlands; Group A), six patients were treated with 
recFSH (Puregon, NV Organon, Oss, The Netherlands) administered i.m. (Group 
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В), and to seven patients Puregon was administered s.c. (Group C). 
The median age (range) and weight (range) of the patients in each group were 
not different (32.0 (27-37) years and 62.0 (47-70) kg in Group A, 34.5 (31-36) 
years and 68.5 (53-75) kg in Group B, 32.0 (30-36) years and 59.5 (53-72) kg 
in group С The median (range) duration of infertility was 3.2 (2-8), 3.6 (1-5) 
and 3.8 (1-8) years in Groups А, В and С respectively. Group A comprised three 
patients with primary infertility, Group В two patients, and Group С one patient. 
The cause of the infertility was unknown for five patients of Group A, the other 
two patients of Group A had tubal pathology. Three patients of Group В had 
tubal pathology, t w o had dysmucorrhea, while one patient had unexplained 
infertility. Group С comprised four patients with tubal pathology, one had 
dysmucorrhea, and two patients had unexplained infertility. 
Treatment 
Administration of the GnRHa buserelin (Suprecur, Hoechst AG, Frankfurt, 
Germany) was started on the first day of the menstrual cycle (150 /yg four times 
per day intranasally). On the 14th day of buserelin treatment the serum 17ß-
oestradiol (E2) concentration was determined and a vaginal ultrasonography was 
performed. If the serum E2 concentration was below 200 pmol/L, gonadotrophin 
administration was started the next day. If an ovarian cyst (diameter larger than 
2 cm) was present and the E2 concentration was below 200 pmol/L, the cyst 
was punctured and aspirated transvaginal^. If the serum E2 concentration was 
higher than 200 pmol/L, the dosage of buserelin was increased to 1200 /yg 
daily. In this case serum E2 determination and ultrasonography were repeated 
one week later and if necessary, every week afterwards. As soon as the E2 
concentration was below 200 pmol/L gonadotrophin treatment was started, the 
buserelin dosage remaining at 1200 μg daily. 
In the stimulation phase of the IVF cycle t w o ampoules (i.e. 150 IU) of hMG or 
recFSH, reconstituted in 1 mL solvent, were injected once daily between 4.00 
and 6.00 p.m. The first day of gonadotrophin treatment was called cycle day 3. 
I.m. injections were given in the upper thigh or the buttock, s.c. injections were 
given in the abdomen using a syringe injector (Monoject, Sherwood Medical, St. 
119 
Louis, USA). The patients were asked to check the injection site 24 hours later 
and to score the items redness, itchiness, swelling, pain and bruising as none, 
mild, moderate or severe. From the second FSH treatment day (cycle day 4) 
onwards, daily blood samples were taken immediately before the next injection. 
The blood samples were centrifuged and serum samples were frozen until 
assayed. Vaginal ultrasound measurements of endometrial thickness and largest 
diameter of all visible follicles were performed every other day before the 
gonadotrophs administration, from cycle day 5 onwards. 
The gonadotropin administration was discontinued when the mean diameter of 
the largest follicle was more than 20 mm, an optimal number of follicles with a 
diameter larger than 15 mm was present (at least three) and the endometrial 
thickness was more than 9 mm. On the day these criteria were fulfilled, an i.m. 
injection of 10 000 IU hCG (Pregnyl, NV Organon, Oss, The Netherlands) was 
given around 12.00 p.m. Buserelin treatment was discontinued after the hCG 
injection. The day after hCG administration a blood sample was taken between 
4.00 and 6.00 p.m. Transvaginal oocyte retrieval was performed 35 hours after 
the hCG injection. A blood sample was taken before ovum pickup. The maturity 
grade of the retrieved oocytes was scored (immature, mature, postmature of 
luteinized). On the third day after oocyte retrieval the quality of all embryos was 
scored according to the criteria of our laboratory (quality score bad, moderate, 
fair, fairly good, or good). Embryotransfer was performed three days after ovum 
pickup. If the embryo quality was at least fairly good, embryos were cryopreser-
ved. 
In the luteal phase of the cycle progesterone (Progestan, NV Organon, Oss, The 
Netherlands) was administered intravaginally in a daily dosage of 400 mg (tid). 
Progesterone treatment was started on the day after oocyte retrieval and 
continued until the day of the pregnancy test (the 18th day after ovum pickup) 
or until the onset of the next menses. Blood samples were taken on the 2nd, 
4th, 6th, 8th and 10th day after ovum pickup. 
The Humegon, Puregon and hCG ampoules were derived from one batch each. 
The in-vivo bioactivity of FSH was 75 IU in the Humegon and Puregon batches, 
the in-vivo bioactivity of LH in the Humegon batch was also 75 IU. The FSH and 
LH immunoreactivity in the ampoules were determined with the same immuno-
assays as were used for the serum samples. In the case of Humegon the FSH 
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¡mmunoreactivity was 42 IU, the LH activity 4.1 IU. The Puregon ampoule 
contained 56 IU FSH and no LH was present. 
Assays 
In all serum samples concentrations of FSH, LH and E2 were determined. Serum 
progesterone (P) concentrations were measured from day 9 of the stimulation 
phase onwards. Serum FSH and LH concentrations were determined by ¡m-
munoradiometric assays, which were previously described (Kremer et al., 
1991). Serum E2 and Ρ concentrations were measured by radioimmunoassays 
(Thomas et al., 1977), except for the serum E2 levels after t w o weeks of 
buserelin treatment, which were determined by a time-resolved fluoroimmunoas-
say (DELFIA, Wallac Oy, Turku, Finland). 
Statistics 
Serum concentrations below the detection limit were assigned the minimum 
detectable concentration for the assay. Differences between the groups were 
evaluated using the Kruskal-Wallis (nonparametric analysis of variance) test. For 
evaluation of hormone concentrations a limited number of characteristics were 
selected, viz. the concentration of FSH, LH, E2 and Ρ on cycle day 11 and the 
day of hCG administration, and median Ρ concentrations between 3 and 10 
days after hCG injection. 
Results 
Cycle characteristics in the three groups are displayed in Table 1. Although the 
numbers of large follicles and retrieved oocytes seemed higher in Group B, there 
were no statistically significant differences between the three groups. 
Figures 1, 2, 3 and 4 depict the median serum FSH, LH, E2 and Ρ concen­
trations from the first FSH treatment day (cycle day 3) until cycle day 11 and 
from the day of hCG administration (P-2) until the 10th day after oocyte 
retrieval. The FSH concentrations on cycle day 11 and the day of hCG ad-
121 
ministration were significantly higher in Group С (s.с. recFSH) than in Groups A 
and В (p < 0.05). The higher FSH concentrations did not result in higher 
numbers of follicles, oocytes or in higher E2 concentrations. Serum LH, E2 and Ρ 
concentrations were not significantly different between the three groups. 
Apparently, exogenous LH administration in Group A did not result in an 
increase in serum LH levels. 
Generally, both the i.m. and s.c. injections were well tolerated. In order to 
summarize the incidence of local reactions, the most adverse local reaction 
scored on all treatment days was recorded. Results are shown in Table 2. None 
of the patients developed anti-human FSH-antibodies (data not shown). Two 
patients in Group A became pregnant, one had a singleton and one a triplet 
pregnancy, and one patient in Group В had a singleton pregnancy. 
Table 1. Cycle characteristics after ovarian stimulation treatment with 150 IU 
hMG i.m., 150 IU recFSH i.m. and 150 IU recFSH s.c. Median values and 
10th and 90th percentiles are presented. 
hMG i.m. recFSH i.m. recFSH s.c. 
number of FSH treatment days 11(10,11) 10(9,11) 10(9,14) 
number of follicles & 10 mm* 
on cycle day 11 10(5,20) 14(11,20) 8(3,26) 
on the day of hCG 12(7,24) 17(11,27) 9(6,28) 
number of follicles г 15 mm' 
on cycle day 11 5(2,9) 10(5,11) 5(1,17) 
on the day of hCG 9(5,15) 12(10,17) 8(6,18) 
number of retrieved oocytes 7(2,18) 11(9,18) 7(5,24) 
percentage mature oocytes 85(75,95) 100(45,100) 83(53,100) 
fertilization rate 86(43,100) 72(62,89) 75(43,76) 
mean embryo quality** 3.3(2.3,5.0) 3.8(2.8,4.5) 4.0(2.7,4.2) 
largest diameter 
scale from 1 (bad) to 5 (good) 
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FSH (lU/L) 
β 7 β β 10 11 p-2 
Day 
Figure 1. 
Figure 2. 
Serum FSH concentrations in 7 patients treated with 150 IU hMG i.m. 
(Group A, solid line), 6 women treated with 150 IU recFSH i.m. (Group B, 
dotted line), and 7 women treated with 150 IU recFSH s.c. (Group C, 
dashed line). Median values are presented. Cycle day 3 is the first day of 
gonadotrophin administration, P-2 is the day of hCG administration, Ρ is 
the day of ovum pickup. 
LH (IU/L) 
Э 4 5 β 7 β 9 10 11 P-2 + 2 + 4 + β + 8 + 1 0 
Day 
Serum LH concentrations in 7 patients treated with 150 IU hMG i.m. 
(Group A, solid line), 6 women treated with 150 IU recFSH i.m. (Group B, 
dotted line), and 7 women treated with 150 IU recFSH s.c. (Group C, 
dashed line). 
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Oestradlol (x10O0 pmol/L) 
4 5 β 7 β S 10 11 P-2 Ρ +2 +4 
Day 
+ S +8 +10 
Figure 3. Serum E2 concentrations in 7 patients treated with 150 IU hMG i.m 
(Group A, solid line), 6 women treated with 150 IU recFSH i.m. (Group B, 
dotted line), and 7 women treated with 150 IU recFSH s.c. (Group C, 
dashed line). 
Progesterone (nmol/L) 
3 4 5 β 7 β В IO 11 Ρ 2 Ρ +2 +4 +β + 8 + 1 0 
Day 
Figure 4. Serum Ρ concentrations in 7 patients treated with 150 IU hMG i.m. 
(Group A, solid line), 6 women treated with 150 IU recFSH i.m. (Group B, 
dotted line), and 7 women treated with 150 IU recFSH s.c. (Group C, 
dashed line). 
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Bruising 
Itching 
Pain 
Redness 
Swelling 
none 
mild 
moderate 
severe 
none 
mild 
moderate 
severe 
none 
mild 
moderate 
severe 
none 
mild 
moderate 
severe 
none 
mild 
moderate 
severe 
Overall local tolerance symptoms 
none 
mild 
moderate 
severe 
hMG im 
85.7 
0.0 
0.0 
14.3 
100.0 
0.0 
0.0 
0.0 
42 .9 
0.0 
57.1 
0.0 
100.0 
0.0 
0.0 
0.0 
100.0 
0.0 
0.0 
0.0 
28.6 
0.0 
57.1 
14.3 
RecFSH im 
66.7 
0.0 
33.3 
0.0 
100.0 
0.0 
0.0 
0.0 
50.0 
16.7 
0.0 
33.3 
100.0 
0.0 
0.0 
0.0 
100.0 
0.0 
0.0 
0.0 
33.3 
16.7 
16.7 
33.3 
RecFSH sc 
42 .9 
28.6 
28.6 
0.0 
85.7 
14.3 
0.0 
0.0 
85.7 
0.0 
14.3 
0.0 
85.7 
0.0 
14.3 
0.0 
100.0 
0.0 
0.0 
0.0 
42 .9 
14.3 
42.9 
0.0 
Table 2. Percentage of the patients with local tolerance symptoms on at least one 
treatment day. 
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Discussion 
RecFSH treatment appeared to be very effective in stimulating multiple follicular 
growth with correspondingly high E2 concentrations. Apparently, in women with 
normal endocrine profiles, the amount of endogenous LH was sufficient to 
stimulate androgen and E2 production within the follicle. Administration of 
exogenous LH appeared not to be necessary. 
Comparison of Groups A and В {¡.m. administration of hMG and recFSH respec-
tively) did not show significant differences between serum FSH, LH and Ρ 
concentrations. As can be seen in Figure 1, the higher FSH immunoreactivity 
contained in the Puregon ampoules did not result in a higher serum FSH level. In 
fact, FSH levels were even slightly lower. Still, the numbers of follicles and 
oocytes and serum E2 concentrations tended to be higher in Group В than in 
Group A. This means that the biological activity of recFSH would be higher than 
that of hMG. Preliminary results of a large multicentre study also suggested a 
higher potency of recFSH in comparison with urinary FSH (Metrodin) (Coelingh 
Bennink, 1994). Differences in biological activity between various preparations 
may be explained by a discrepancy in the isohormone profiles. Matikainen er al. 
(1994) reported that recFSH contained more basic isoforms than urinary FSH 
(Metrodin). More basic isoforms have a higher in-vitro bioactivity and a higher 
receptor affinity than more acidic isoforms (Wide and Hobson, 1986). When a 
single i.m. injection of recFSH or Metrodin was given to gonadotrophin-deficient 
subjects, the ratio of FSH in-vitro bioactivity and immunoreactivity in serum was 
significantly higher after recFSH than after urinary FSH administration, up to 72 
hours after injection. In contrast with Matikainen et al., De Boer and Mannaerts 
(1990) described similar isohormone profiles of recFSH and Metrodin. Maybe 
batch-to-batch differences contribute to this discrepancy. 
Comparing s.c. recFSH treatment with i.m. treatment, a significantly higher 
serum FSH concentration was observed. Le Cotonnec et al. (1994) performed a 
pharmacokinetic study in pituitary down-regulated women comparing single 
intravenous, i.m. and s.c. injections of 150 IU recFSH (Gonal-F). They estimated 
comparable terminal half-lives after i.m. and s.c. administration (37 ± 25 
hours). The systemic bioavailability was 61 ± 18 % after i.m. and 74 ± 29 % 
after s.c. administration. The difference was statistically not significant, but a 
higher bioavailability after s.c. administration could explain the higher FSH 
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concentration we observed in our study. 
Although we measured significantly higher FSH immunoreactivity in serum after 
s.c. treatment, there was no increase in numbers of follicles or oocytes. On the 
contrary, the numbers of follicles and oocytes even tended to be lower after s.c. 
than after i.m. recFSH treatment, and were comparable to the results after hMG 
treatment. A possible explanation could be that the bioactive to immunoreactive 
ratio was be lower after s.c. than after i.m. treatment. However, this seems 
unlikely since serum FSH concentrations after i.m. or s.c. administration showed 
a similar pattern (Le Cotonnec et al., 1994). It is not to be expected that the 
metabolism of different isoforms of recFSH will be influenced by the subsequent 
i.m. or s.c. route of administration with a difference in biological effect as a 
result. Thus, the reason for the observed differences remains unclear. 
The s.c. route of administration was well tolerated by all patients in Group C. 
All the women of this group could perform the injections themselves, whereas 
in the case of the other groups, the injections were mostly given by the partner 
or by trained personnel. Obviously, self-administration is a great advantage of 
the s.c. over the i.m. administration route. 
In conclusion, recFSH can be considered to be as effective as hMG, and 
exogenous LH is not necessary for adequate ovarian stimulation in women with 
normal endocrine profiles, even during pituitary suppression. Also, subcutaneous 
recFSH treatment is effective and well tolerated. 
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Chapter 8 
Follicular fluid hormone concentrations after ovarian 
stimulation using gonadotrophic preparations with 
differentFSH/LH ratios. I. Comparison of an FSH-
dominant and a purified FSH preparation 
U.M. Duijkers, W.N.P. Willemsen, J.M.G. Hollanders, C.J.CM. Hamilton, 
C.M.G. Thomas, H.M. Vemer 
submitted 
Abstract 
The aim of the present randomized study was to investigate whether ovarian stimu-
lation treatment with gonadotrophic preparations containing different amounts of LH 
activity resulted in variations of steroidal composition of follicular fluid. A different 
endocrine milieu within the follicle might influence oocyte quality. Antral fluid from 
mature follicles was collected in in vitro fertilization cycles and concentrations of 
testosterone, androstenedione, oestrone, oestradiol, progesterone, follicle-stimulating 
hormone (FSH) and luteinizing hormone (LH) were determined. A comparison was made 
between treatment with a purified FSH preparation (9 patients, 35 follicular fluid 
samples) and an FSH dominant human menopausal gonadotrophin (hMG) preparation (9 
patients, 34 samples). No differences in any of the hormone levels could be detected 
between the two groups. 
In conclusion, treatment with gonadotrophic preparations containing different FSH/LH 
ratios did not result in different androgen, oestrogen and progesterone levels in follicular 
fluid 
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Introduction 
chapter 8 
The generally accepted theory for the mechanism of oestradiol (E2) production 
by the ovary is the two-cell two-gonadotrophin concept (Armstrong and Dor-
rington, 1977). This concept means that luteinizing hormone (LH) stimulates 
androgen synthesis in cells of the theca interna around the ovarian follicle 
(McNatty et al., 1984). Thecal androgens are transported to the granulosa cells, 
where they are aromatized into oestrogens (Edwards et al., 1980). Follicle-
stimulating hormone (FSH) stimulates the necessary aromatase activity in the 
granulosa cells (Erickson et al., 1979, Yong er al., 1992). The oestrogens are 
secreted into the follicular fluid and the blood circulation. As the follicle matures, 
the E2 concentration in follicular fluid increases significantly (Edwards et al., 
1980). 
If ovarian hyperstimulation treatment is applied, for instance in in vitro fer-
tilization (IVF) cycles, different stimulation protocols can be used. In general, the 
administration of a gonadotrophin preparation is preceded by and combined with 
administration of a gonadotrophin releasing hormone agonist (GnRHa). Several 
gonadotrophin preparations containing FSH and LH activity in various amounts, 
can be applied for ovarian stimulation. In the present study we investigated 
whether treatment with gonadotrophic preparations containing different 
amounts of LH activity resulted in a different steroid composition in the antral 
fluid of mature follicles. Thus it was tested whether lower amounts of exoge-
nous LH led to a decrease in androgen production by the thecal cells, to lower 
E2 production by the granulosa cells and to lower follicular fluid E2 concentra-
tions. Differences in the endocrine milieu of the oocyte might influence oocyte 
quality. In a randomized study in IVF patients, treatment with purified urinary 
FSH was compared with a gonadotrophic preparation comprising FSH and LH 
activity in a ratio of 3 : 1 . Concentrations of androgens, oestrogens, proge-
sterone, FSH and LH in follicular fluid were compared. 
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Materials and methods 
Patients 
Twenty women undergoing IVF treatment for tubal pathology or unexplained 
infertility participated in the study. The inclusion criteria were: age between 20 
and 40 years, normal endocrine serum profile in the early follicular phase of the 
cycle (FSH concentration below 8 IU/L, LH/FSH ratio less than 3, testosterone 
concentration below 2.5 nmol/L, prolactin concentration below 700 mlU/L and 
thyroxin concentration between 58 and 148 nmol/L), no hormonal medication 
for at least two menstrual cycles prior to the study, no endometriosis observed 
on laparoscopy, both ovaries present, and no male subfertility (at least 20x10e 
sperm/mL, at least 50% motile sperm, motility grade at least fairly good, at least 
60% morphologically normal sperm and absence of antisperm antibodies as 
confirmed by the direct immunobead test, or a fertilization rate of at least 50% 
if the patient had had IVF before). 
The study was approved by the hospital's Ethical Committee and all the women 
gave their informed consent. 
Treatment protocol 
The women were randomly divided into two groups: one group of 10 women 
was treated with purified urinary FSH (ratio FSH/LH activity > 60, Metrodin, 
Serono, Pharma-lmport BV, Haarlem, Netherlands): Group A, the other group of 
10 women was treated with a preparation containing FSH and LH activity in a 
ratio of 3:1 (Normegon, NV Organon, Oss, Netherlands): Group B. Each prepara-
tion was administered intramuscularly (i.m.) in a fixed daily dose of 150 IU. 
Details about IVF results and serum hormone levels were published previously 
(Duijkers et al., 1993). 
Gonadotrophs administration was combined with buserelin (Suprefact, Hoechst 
AG, Frankfurt, Germany) treatment, which started on day 21 of the menstrual 
cycle, in a daily dose of 900 pg intranasally. On the tenth day of buserelin 
treatment, the serum E2 concentration was determined by time-resolved fluo-
roimmunoassay (DELFIA, Wallac Oy, Turku, Finland). If the E2 concentration 
was below 500 pmol/L administration of gonadotrophins was started the next 
day, if the serum E2 concentration was still higher than 500 pmol/L, the ad-
134 
chapter 8 
ministration of gonadotrophins was postponed until it was below 500 pmol/L. 
Buserelin administration was continued until the day of human chorionic 
gonadotrophin (hCG) administration. 
Transvaginal ultrasonography was performed every other day during the 
stimulation phase of the IVF cycle to measure follicular growth. Serum E2 
concentrations were determined by the time-resolved fluoroimmunoassay 
procedure. The administration of gonadotrophins was discontinued as soon as at 
least three follicles were present with a (largest) diameter > 15 mm, one of 
which had a diameter ^ 20 mm, and the serum E2 concentration was ap-
proximately 1000 pmol/L per large follicle ( > 15 mm). In one patient of each 
group the IVF treatment had to be cancelled before oocyte retrieval because of a 
significant drop in E2 levels. 
Transvaginal ultrasound-guided oocyte retrieval was performed 35 hours after 
the hCG injection. Follicular fluid from the four largest follicles was collected 
separately. In three patients fluid from only three follicles could be collected. 
The follicular fluid was not diluted with flushing medium or fluid from another 
follicle. The fluid was centrifuged for 10 minutes at 2000xg and stored at -20°C 
until assayed. Embryo transfer was performed on the third day after oocyte 
retrieval. The luteal phase of the cycle was supported by i.m. hCG injections. 
Assays 
Concentrations of E2 and progesterone in follicular fluid were determined by 
radioimmunoassays (RIA), which were described earlier (Thomas et al. 1977). 
Concentrations of oestrone (Heineman et al., 1984), testosterone (Dony et al., 
1985) and androstenedione (Van Duren, 1988) were determined by RIAs 
developed in this laboratory. Concentrations of FSH and LH were measured by 
immunoradiometric assay (IRMA) procedures (Kremer et al. 1991). 
Statistics 
Results are expressed as median values with tenth and ninetieth percentiles. 
Statistical analysis was performed using the two-sample Wilcoxon test (rank 
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sum test). Correlations were detected by Spearman's rank correlation test. 
Differences with Ρ < 0.01 were considered significant. The two cancelled 
cycles were not included in the evaluation. 
Table 1. Cycle characteristics of the study groups: number of patients, number of 
treatment days, median number of follicles larger than 15 mm and median 
serum E2 and LH concentration on the day of hCG administration, median 
number of retrieved oocytes and median fertilization rate (percentage 
fertilized oocytes). Tenth and ninetieth percentiles in parentheses. 
Group A Group В 
treatment 
number of patients 
number of treatment days 
η follicles S15 mm 
serum E2 (pmol/L) 
serum LH (IU/L) 
η oocytes 
fertilization rate (%) 
Metrodin 
9 
9(9,15)* 
6 (5,11) 
5700(2200,9800) 
1.6(1.1,2.9)' 
8 (6,11) 
67(22,100) 
Normegon 
9 
8 (7,10)* 
9(4,19) 
7500(4240,13400) 
3.2(1.7,4.0)' 
13 (5,21) 
63(14,100) 
0.01 < Ρ < 0.05 
Results 
Table 1 lists the cycle characteristics of the two groups. Serum LH con­
centrations were higher in Group В than in Group A on the day of hCG ad­
ministration (0.01 < Ρ < 0.05), which might be an effect of administration of 
exogenous LH in Group B. This observation is rather unexpected since the half-
life of LH is very short (Diczfalusy and Harlin, 1988). The total number of 
follicular fluid samples was 35 in Group A and 34 in Group B. Median values of 
the hormone concentrations in the three or four collected follicular fluid samples 
were calculated for each patient. The median value of these individual median 
concentrations was determined in each group. The results are listed in Table 2. 
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Table 2. Median values of individual median concentrations of testosterone, 
androstenedione, oestradiol, oestrone, progesterone, LH and FSH in fol­
licular fluid after ovarian stimulation treatment with Metrodin (Group A, 9 
women) or Normegon (Group B, 9 women). Tenth and ninetieth percen­
tiles are given in parentheses. 
Group A Group В 
Treatment 
Number of samples 
Testosterone (nmol/L) 
Androstenedione (nmol/L) 
Oestradiol (//mol/L) 
Oestrone (nmol/L) 
Progesterone Ц/mol/L) 
LH (lU/L) 
FSH (lU/L) 
Metrodin 
35 
13.5 
57 
2.6 
150 
33 
<1.0 
1.6 
(8.0;19.5) 
(23;144) 
(1.4;3.8) 
(104;204) 
(23;52) 
(1.3;2.2) 
Normegon 
34 
13.0 
42 
2.6 
160 
32 
<1.0 
1.7 
(8.2;15.0) 
(26;153) 
(1.5;3.7) 
(120;263) 
(19;53) 
(1.0;2.7) 
There were no significant differences between the two groups for any of the 
determined hormones. 
Follicular fluid steroid levels were considerably higher than serum steroid levels. 
Androstenedione and testosterone concentrations were about ten times higher 
than the normal serum concentrations. Oestrone, E2 and progesterone con­
centrations were about thousand times higher than serum levels. The elevated 
progesterone levels indicated that the process of luteinization following hCG 
administration already started. Concentrations of FSH were lower than in serum, 
and LH concentrations in follicular fluid were undetectably low. 
No significant correlations were found between the individual fertilization rates 
(percentage fertilized oocytes) and median concentrations of testosterone, 
androstenedione, oestrone, E2, androgens (testosterone plus androstenedione), 
oestrogens (oestrone plus E2), the androgen/oestrogen ratio and the progeste-
rone/E2 ratio. A positive correlation existed between the fertilization rate and 
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progesterone concentrations ¡η Group В (Р<0.01), but not in Group A. 
Discussion 
The two gonadotrophs preparations used in the present study contain different 
amounts of LH activity. Reducing the amount of exogenous LH may result in 
less LH stimulation of the ovary. This might affect the rate of androgen produc­
tion by the theca cells and subsequent oestrogen production in the granulosa 
cells. Lower amounts of exogenous LH may therefore result in a decrease of 
androgen and oestrogen levels in follicular fluid. 
In both study groups, high androgen and oestrogen levels were present in 
follicular fluid. Comparing treatment with purified FSH (Group A) and an FSH-
dominant hMG preparation (Group B), no differences were seen in the median 
concentrations of steroids and of FSH and LH. No evidence for a decrease in 
follicular fluid E2 concentrations after treatment with the preparation with the 
lowest LH content could be found. Thus, the endocrine milieu of the oocyte 
appeared to be similar in the two groups. 
However, a comparison between the two groups can only be made with a 
certain reserve. One of the criteria for hCG administration was a serum E2 con­
centration of 1000 pmol/L per large follicle. If, as we already stated, the E2 
production was indeed lower in the group with the lowest exogenous LH 
administration (Group A), also serum E2 levels would be lower. Since the serum 
E2 level had to reach a certain level before hCG was administered, this would 
mean that oocyte retrieval would be postponed, and the follicles would be more 
mature at the time of ovum pickup. Indeed, the number of treatment days was 
higher in Group A than in Group B. Since maturation of the follicle has an impact 
on the steroidal composition of the follicular fluid {McNatty et al., 1979), this 
could mean that the t w o groups were not completely comparable. 
Several studies on the steroidal composition of follicular fluid in IVF cycles were 
performed previously (Frederick et al., 1 9 9 1 , Hartshorne, 1989, Suchanek et al. 
1994, Tarlatzis et al., 1993). Generally, in comparison with our results, similar 
values of oestradiol, androstenedione, testosterone and progesterone were 
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found. Only minor differences between the results of the studies were observed, 
but these may be caused by the use of different RIAs and by variations in the 
stimulation protocol. Suchanek et al. (1994) described mean FSH levels in 
follicular fluid (10.6 IU/L) that were higher than the FSH concentrations in our 
study. The discrepancy may be explained by the assay used: Suchanek et al. 
applied a RIA, while we used an IRMA. 
In summary, in the present study steroid concentrations in follicular fluid were 
similar after ovarian stimulation with an FSH-dominant or a purified FSH prepara-
tion. 
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Follicular fluid hormone concentrations after ovarian 
stimulation using gonadotrophic preparations with 
different FSH/LH ratios. II. Comparison of h M G and 
recombinant FSH 
U . M . Duijkers, W.N.P. Willemsen, J.M.G. Hollanders, C.J.C.M. Hamilton, 
С.M.G. Thomas, H.M. Vemer 
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Abstract 
A small amount of luteinizing hormone (LH) is necessary for 17ß-oestradiol (E2) 
production in the ovarian follicle. Human menopausal gonadotrophin (hMG) contains 
equal amounts of FSH and LH activity, whereas recombinant follicle-stimulating 
hormone (FSH) is a gonadotrophin preparation without LH. The aim of the present 
randomized study was to investigate whether ovarian stimulation treatment with recom-
binant FSH or hMG resulted in different steroidal composition of follicular fluid. Antral 
fluid from mature follicles was collected in in vitro fertilization cycles and concentrations 
of testosterone, androstenedione, oestrone, E2, progesterone, FSH and LH were 
determined. Seven patients (27 samples) were treated with hMG, six patients (22 
samples) with recombinant FSH. Androgen, oestrogen, progesterone and FSH con-
centrations in follicular fluid tended to be lower in the group treated with recombinant 
FSH, but the variation was large and differences were statistically not significant. In 
conclusion, treatment with a gonadotrophin preparation containing no LH resulted in 
adequate androgen and oestrogen levels in antral fluid of the ovarian follicle in women 
with normal endocrine profiles, even during pituitary suppression by a gonadotrophin-
releasing hormone agonist. 
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Introduction 
Recombinant human follicle-stimulating hormone (recFSH) is produced by a 
Chinese hamster ovary cell line transfected with the human FSH α- and ß-
subunit genes (Van Wezenbeek et al., 1990). It is a pure FSH preparation, 
completely devoid of luteinizing hormone (LH) activity, in contrast with purified 
urinary FSH preparations. The development of recFSH has offered an oppor-
tunity to test the two-cell two-gonadotrophin hypothesis. This hypothesis means 
that LH stimulates the production of androgens in the theca cells of the ovarian 
follicle, while FSH stimulates aromatization of the androgens into oestrogens in 
the granulosa cells. The produced oestrogens are then secreted into follicular 
fluid and into the blood circulation. 
The two-cell two-gonadotrophin theory has been confirmed by studies in 
hypophysectomized immature rats (Mannaerts et al., 1991). RecFSH treatment 
augmented ovarian weight, while serum 17ß-oestradiol (E2) concentrations 
remained low. A clinical study in a gonadotrophin-deficient woman showed that 
recFSH administration stimulated multiple follicular growth, without a con-
comitant increase in serum E2 levels (Schoot et al., 1992). Concentrations of 
androgens and oestrogens in follicular fluid were extremely low. Thus, LH 
appeared to be necessary for adequate ovarian stimulation with correspondingly 
high serum E2 concentrations. 
Devroey et al., (1994) showed that in in vitro fertilization (IVF) cycles, during 
pituitary suppression with gonadotrophin releasing hormone agonists (GnRHa), 
recFSH administration resulted in multiple follicular growth with adequate serum 
E2 levels. So the low amount of endogenous LH, still present despite pituitary 
suppression by a GnRHa, apparently was sufficient for stimulation of the theca 
cells to produce androgens which were aromatized into E2. Still, lower LH stimu-
lation of the ovary might result in a decrease of androgen production by the 
thecal cells, lower E2 production by the granulosa cells and lower follicular fluid 
E2 concentrations. In the present randomized study in IVF cycles, we compared 
steroid levels in the antral fluid of mature follicles after recFSH and hMG 
treatment. Because follicular fluid is the endocrine environment of the oocyte, 
differences in the steroidal composition might affect oocyte quality. 
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Materials and methods 
Patients 
Thirteen women undergoing IVF treatment for tubal pathology or unexplained 
infertility participated in the study. The inclusion criteria were: age between 20 
and 40 years, normal endocrine serum profile in the early follicular phase of the 
cycle (FSH concentration below 8 IU/L, LH/FSH ratio less than 3, testosterone 
concentration below 2.5 nmol/L, prolactin concentration below 700 mlU/L and 
thyroxin concentration between 58 and 148 nmol/L), no hormonal medication 
for at least two menstrual cycles prior to the study, no endometriosis observed 
on laparoscopy, both ovaries present, body weight between 80 and 130% of 
the ideal weight (according to the Metropolitan Height and Weight Tables), and 
no severe male subfertility of the partner (at least 20x106 sperm/mL, at least 
30% motile sperm, motility grade at least fairly good, at least 4 0 % mor-
phologically normal sperm and absence of antisperm antibodies as confirmed by 
the direct immunobead test, or a fertilization rate of at least 50% if the patient 
had had IVF before). 
The study was approved by the hospital's Ethical Committee and all the women 
gave their informed consent. 
Treatment protocol 
The women were randomly divided into two groups: seven women were treated 
with hMG (Humegon, NV Organon, Oss, Netherlands): Group A, six women 
received recFSH (Puregon, NV Organon, Oss, Netherlands): Group B. Both 
preparations were administered intramuscularly (i.m.) in a fixed daily dose of 
150 IU. 
In each group the gonadotrophin administration was combined with buserelin 
(Suprecur, Hoechst AG, Frankfurt, Germany) treatment, which was started on 
day 1 of the menstrual cycle, in a daily dose of 600 ^g intranasally. On the 14th 
day of buserelin treatment the serum E2 concentration was measured by time-
resolved fluoroimmunoassay (DELFIA, Wallac Oy, Turku, Finland). If E2 was 
below 200 pmol/L, gonadotrophin administration was started the next day, if 
the E2 concentration was still higher than 200 pmol/L, the administration of 
gonadotrophins was postponed until the E2 level was below 200 pmol/L. 
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Buserelin administration was continued until the day of human chorionic 
gonadotrophin (hCG) administration. 
Transvaginal ultrasonography was performed every other day during the 
stimulation phase of the IVF cycle to measure follicular growth and endometrial 
thickness. The administration of gonadotrophins was discontinued as soon as at 
least three follicles had a (largest) diameter > 15 mm, the mean diameter of the 
largest follicle was > 20 mm, and the endometrial thickness was à 9 mm. On 
the day these criteria were fulfilled, 10000 IU of hCG were administered i.m. 
between 11.00 and 12.00 p.m. 
Transvaginal ultrasound-guided oocyte retrieval was performed 35 hours after 
the hCG injection. Follicular fluid from the four largest follicles was collected 
separately. In three patients the fluid from only three follicles could be collected. 
The follicular fluid was not diluted with flushing medium or fluid from another 
follicle. The fluid was centrifuged and stored at -20°C until assayed. Embryo 
transfer was performed on the third day after oocyte retrieval. The luteal phase 
of the cycle was supported with progesterone, administered intravaginally. 
Assays 
Concentrations of E2 and progesterone in follicular fluid were determined by 
radioimmunoassays (RIA), which were described earlier (Thomas et al. 1977). 
Concentrations of oestrone (Heineman et al., 1984), testosterone (Dony et al., 
1985) and androstenedione (Van Duren et al., 1988) were determined by RIAs 
developed in this laboratory. Concentrations of FSH and LH were measured by 
immunoradiometric assay (IRMA) procedures (Kremer et al. 1991). 
Statistics 
Results are expressed as median values with tenth and ninetieth percentiles. 
Statistical analysis was performed using the two-sample Wilcoxon test (rank 
sum test). Correlations were detected by Spearman's rank correlation test. Dif-
ferences with Ρ < 0.01 were considered significant. 
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Table 1. Cycle characteristics of the study groups: number of patients, number of 
treatment days, median number of follicles larger than 15 mm and median 
serum E2 and LH concentration on the day of hCG administration, median 
number of retrieved oocytes, median fertilization rate. Tenth and ninetieth 
percentiles in parentheses. 
treatment 
number of patients 
number of treatment days 
η follicles ä 15 mm 
serum E2 (pmol/L) 
serum LH (IU/L) 
η oocytes 
fertilization rate (%) 
Group A 
Humegon 
7 
11 (10,11) 
9(5,15) 
6100(3660,15400) 
1.4(1.3,1.8) 
7 (2,18) 
86(43,100) 
Group В 
Puregon 
6 
10(9,11) 
12(10,17) 
7550(5400,11450) 
1.4(0.9,2.8) 
11 (9,18) 
73 (62,89) 
Results 
Characteristics of the IVF cycles are listed in Table 1. Median serum LH con­
centrations were equal in the two groups, so administration of exogenous LH in 
the case of Group A did not result in an increase in serum LH levels of this 
group as compared to the Puregon group. The total number of follicular fluid 
samples was 27 in Group A and 22 in Group B. Median values of the hormone 
concentrations in the three or four collected follicular fluid samples were 
calculated for each patient. The median value of these individual median concen­
trations was determined in each group. The results are listed in Table 2. 
In both groups high levels of androgens and oestrogens were present in follicular 
fluid. Testosterone, androstenedione, E2, oestrone, progesterone and FSH levels 
tended to be lower in Group В than in Group A, but inter- and intra-individual 
variations were rather large and the observed differences were not statistically 
significant. LH concentrations in follicular fluid were undetectably low in both 
groups, so administration of exogenous LH did not result in measurable LH 
immunoreactivity in antral fluid. No significant correlations were detected 
between the individual fertilization rates and median concentrations of tes-
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tosterone, androstenedione, androgens (testosterone plus androstenedione), E2, 
oestrone, oestrogens (E2 plus oestrone), progesterone, the androgen/oestrogen 
ratio or the progesterone/E2 ratio in follicular fluid. 
Table 2. Median values of individual median concentrations of testosterone, 
androstenedione, oestradiol, oestrone, progesterone, LH and FSH in 
follicular fluid after ovarian stimulation treatment with Humegon (Group 
A, 7 women) or Puregon (Group B, 6 women). Tenth and ninetieth 
percentiles in parentheses. 
Humegon Puregon 
Number of samples 
Testosterone (nmol/L) 
Androstenedione (nmol/L) 
Oestradiol Ц/mol/L) 
Oestrone (nmol/L) 
Progesterone (¿/mol/L) 
LH (IU/L) 
FSH (IU/L) 
27 
14.5 
33 
2.4 
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40 
<1.0 
2.2 
(9.4;23.5) 
(16;80) 
(1.3;3.1) 
(66;240) 
(18;57) 
(<1.0;<1.0) 
(1.9;3.5) 
22 
11.0 
19 
1.4 
125 
31 
<1.0 
1.7 
(6.1;20.0) 
(14;77) 
(0.7;3.2) 
(54;245) 
(20;39) 
(<1.0;<1.0) 
(1.2;4.5) 
Discussion 
Administration of exogenous LH did not result in an increase of serum LH levels 
in the group treated with hMG, probably because of the short half-life of LH 
contained in this preparation (Diczfalusy and Harlin, 1988). However, binding to 
the LH receptors in the theca interna might occur before elimination from the 
circulation has occurred. Differences in LH binding in the ovary might influence 
the steroidal composition of follicular fluid, and subsequently affect oocyte 
quality. 
Theoretically, one would expect that more LH stimulation of the ovary would 
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lead to an increase of the E2 concentration in follicular fluid for several reasons. 
First, LH stimulates androstenedione production in the theca interna (McNatty et 
al., 1984). Androstenedione is converted to testosterone or to oestrone and 
then to E2 in the granulosa cells by 17ß-hydroxysteroid dehydrogenase and 
aromatase. Next, E2 is secreted into the follicular fluid (McNatty et al., 1981). 
Thus, an increase in androstenedione concentrations would lead to higher 
follicular fluid E2 levels. Secondly, LH stimulates aromatase activity of granulosa 
cells from mature follicles (Yong et al., 1994). Higher testosterone and E2 
concentrations also stimulate FSH enhancement of aromatase activity (Daniel 
and Armstrong, 1980, Hillier er al., 1982) which would further increase E2 
production by the granulosa cells and E2 levels in follicular fluid. E2 in turn 
enhances the LH stimulation of androgen production (Roberts and Skinner, 
1990). All described effects of LH point at the same direction: more LH stimula-
tion of the ovary invariably leads to higher E2 concentrations in follicular fluid. 
LH also increases progesterone production in mature granulosa cells (Yong et 
al., 1994), which will result in higher progesterone concentrations in follicular 
fluid. The produced progesterone will serve as a potential precursor for andro-
gen synthesis by the theca cells, and the androgens in turn are further aroma-
tized to oestrogens by the granulosa cells (Liu and Hsueh, 1986). 
In the group treated with recFSH (Group B) androstenedione, oestrone, E2 and 
progesterone concentrations in follicular fluid tended to be lower than in the 
group treated with hMG (Group A), which would support the theory of short-
ness of LH activity leading to a decrease of androgen, oestrogen and progeste-
rone production. However, there appears to be a large inter- and intra-individual 
variation and the differences are statistically not significant. FSH concentrations 
in follicular fluid were slightly lower in Group В than in Group A. FSH stimulates 
aromatase activity, so lower FSH levels will result in a decrease in E2 production 
(Erickson et al., 1979). Furthermore, FSH induces granulosa cell receptors for 
LH (Kessel et al., 1985, Jia et al., 1986), making granulosa cells more respon­
sive to LH Stimulation of aromatase activity. The lower FSH levels in follicular 
fluid in Group В might therefore also be partly responsible for the slightly lower 
follicular fluid oestrogen concentrations in Group B. 
In conclusion, in women with normal endocrine profiles, recFSH treatment 
resulted in adequate androgen and oestrogen levels in antral fluid of the ovarian 
follicle, even during pituitary suppression by a GnRH-agonist. Thus, in contrast 
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with gonadotrophin-deficient women (Schoot et al., 1992), endogenous LH 
levels appeared to be sufficient to stimulate androgen production by the theca 
cells. Androgen and oestrogen concentrations in follicular fluid were only slightly 
lower after recFSH treatment than after hMG treatment, so the endocrine 
environment of the oocyte will be quite similar. The observed minor differences 
were not statistically significant. It is proposed to conduct a larger study to 
provide evidence whether androgen and oestrogen concentrations were indeed 
lower when no exogenous LH was administered. 
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Part IV 

Chapter 10 
Summary and general discussion 
Gonadotrophs preparations purified from urine of postmenopausal women were 
introduced in the 1960s (Lunenfeld et al., 1960). Since then, these preparations 
have been used on a large scale to stimulate follicular growth in anovulatory 
women. The development of the in vitro fertilization (IVF) technique in the 
1970s brought another indication for the use of gonadotrophins, namely the 
induction of multiple follicular growth in normocyclic women. Human menopau-
sal gonadotrophin (hMG) is the oldest and most frequently used gonadotrophs 
preparation. It contains equal amounts of follicle-stimulating hormone (FSH) and 
luteinizing hormone (LH) activity. Human chorionic gonadotrophin (hCG) is 
added to the preparation and is responsible for part of the LH bioactivity. 
In this thesis we described a number of studies, which were performed to 
increase our knowledge on gonadotrophins. The effect of gonadotrophin 
administration on hormonal parameters and on follicular growth was investigated 
in IVF cycles, since in these cycles oocyte and embryo quality and the com-
position of follicular fluid can be studied. The study subjects were women with 
normal endocrine profiles, suffering from tubal or unexplained infertility. Due to 
strict selection criteria the study groups could be relatively small, while the 
treatment cycles were intensively monitored. As in these studies, administration 
of gonadotrophins in IVF cycles is usually combined with a gonadotrophin relea-
sing hormone agonist (GnRHa), suppressing endogenous gonadotrophin release. 
Prior to our studies of daily gonadotrophin administration in IVF cycles, we 
investigated the effect of a single hMG administration, in combination with 
GnRHa (buserelin) treatment. Routinely, hMG is administered through the 
intramuscular (i.m.) route. Serum patterns of FSH, LH and hCG were described 
after a single i.m. injection of 150 IU hMG (Humegon) (Chapter 2). Alternative 
ways of gonadotrophin administration have been described in literature, namely 
the pulsatile intravenous (i.v.) and the subcutaneous (s.c.) route (Prak et al., 
1992, Howies et al., 1994). Since we planned to apply these alternative routes 
in our IVF studies, we also investigated the effect of a single i.v. and a single 
s.c. injection of 150 IU hMG (Chapters 2 and 3). Obviously, FSH levels showed 
a different pattern after ¡.v. than after i.m. injection, but the pattern of FSH 
concentrations after s.c. administration closely resembled that after i.m. 
injection. The use of sensitive and specific immunoassays enabled us to 
discriminate between LH and hCG immunoreactivity. Exogenous LH concen-
trations could hardly be detected after administration of 150 IU hMG, especially 
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after ¡.m. and s.с. injection, because of the interference of endogenous LH. 
Therefore, a study with a different design was performed to study pharmaco­
kinetic parameters of LH, hCG and also of FSH (Chapter 4). A depot GnRHa 
preparation (triptorelin) was used, which was supposed to suppress endogenous 
LH and FSH levels more adequately than buserelin nasal spray. A single injection 
of 225 IU hMG (Humegon or Pergonal) was given intravenously. The half-life of 
FSH was estimated to be 22 hours, the half-life of hCG approximately 15 hours. 
Exogenous LH could indeed be measured, but disappeared too fast to make a 
reliable estimation of its half-life. 
Subsequently, the effect of multiple hMG administration was studied in IVF 
cycles. In all cycles a fixed daily dose of gonadotrophins was given, since 
adjustment of the dosage according to the individual response could mask 
differences in effect. The standard treatment schedule was investigated in the 
study described in Chapter 5. A daily dose of 150 IU hMG (Humegon) was 
administered i.m., in combination with GnRHa (buserelin) treatment. The effect 
on follicular development and serum levels of FSH, LH, hCG, 17ß-oestradiol and 
progesterone was studied. The standard treatment was compared with pulsatile 
i.v. administration of hMG. A previous non-randomized study described an 
increase in the pregnancy rate after pulsatile i.v. hMG treatment (Prak et al., 
1992). In our randomized experiment we were not able to demonstrate any 
differences in follicular development, endocrine parameters, and oocyte and 
embryo quality between the two administration routes. Since we could not find 
any indications for a possible beneficial effect of pulsatile i.v. treatment, we 
decided not to perform further studies applying this administration route. 
HMG contains FSH and LH bioactivity in a ratio of 1:1. Lately, a tendency exists 
to use gonadotrophic preparations with less LH activity. In animal studies, 
excessive LH activity was detrimental to follicular development (Chandrasekhar 
et al., 1988, Opavsky and Armstrong, 1989). On the other hand, a low amount 
of LH is necessary for adequate ovarian stimulation (Schoot et al., 1992). We 
performed two studies using gonadotrophic preparations with reduced LH 
activity and compared the efficacy of the various preparations. In Chapter 6 we 
described a randomized study comparing treatment wi th Normegon, an hMG 
preparation without addition of hCG, comprising FSH and LH activity in a ratio 
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of 3 : 1 , and Metrodin, a purified FSH preparation with an FSH/LH ratio of more 
than 6 0 : 1 . Adequate ovarian stimulation was seen in both groups, so apparently 
the amount of LH was sufficient for follicular development and steroid produc-
tion within the follicles. 
Metrodin, purified urinary FSH, still contains a minor amount of LH activity. The 
recently developed recombinant human FSH is completely devoid of LH activity. 
This preparation is produced by genetically engineered Chinese hamster ovary 
cells and appears to be almost identical to urinary FSH. The recombinant FSH 
preparation has a much higher biochemical purity than urinary preparations. 
Probably, recombinant FSH will eventually replace urinary hMG and FSH 
preparations. We compared the effect of i.m. hMG (Humegon) and recombinant 
FSH (Puregon) administration in IVF cycles (Chapter 7). In both groups multiple 
follicular growth and adequate serum steroid levels were observed. Apparently, 
administration of exogenous LH was not necessary for ovarian stimulation, even 
during suppression of endogenous LH levels by a GnRH agonist. Comparison of 
the steroid composition of follicular fluid after treatment with the various 
preparations (Normegon, Metrodin, Humegon, Puregon) did not show significant 
differences (Chapters 8 and 9). This confirms the observation that, at least in 
our study population, the amount of exogenous LH was not essential for 
follicular growth and steroid production. 
The high biochemical purity of recombinant FSH enables s.c. administration. 
Subcutaneous injections are preferable to i.m. injections, since self-ad-
ministration is more feasible and s.c. injections may be less painful. We com-
pared the efficacy and local tolerance of i.m. and s.c. administration of recom-
binant FSH (Chapter 7). Both administration routes appeared to be effective and 
well tolerated. 
Minor differences were observed between the study groups in the various 
studies. The numbers of follicles and oocytes tended to be lower after Metrodin 
than after Normegon treatment. This difference might be due to the lower 
amount of LH in Metrodin. However, when i.m. recombinant FSH was compared 
with hMG treatment, numbers of follicles and oocytes tended to be even higher. 
So probably the amount of LH was not the explanation for the observed minor 
differences. Another explanation may be a difference in isohormone profiles 
between the preparations. More basic isoforms of FSH appear to have different 
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¡n-vitro and in-vivo bioactivity and receptor affinity than more acidic isoforms 
(Manjunath et al., 1982, Wide and Hobson, 1986). The distribution of the 
isoforms may differ between the various gonadotrophic preparations, which can 
explain differences in biopotency (Harlin et ah, 1986). 
In conclusion, we gained more insight into the kinetics of gonadotrophins and 
we described that the efficacy of gonadotrophic treatment was not influenced 
by the administration route. Gonadotrophic preparations with reduced amounts 
of LH still resulted in adequate ovarian stimulation in women with normal 
endocrine profiles, even during pituitary suppression by a GnRH agonist. Even 
more promising were the results of treatment with a pure FSH preparation 
produced by recombinant DNA techniques, for the future of infertility therapy. 
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Samenvatting 
Gonadotrofinenpreparaten gezuiverd uit urine van postmenopauzale vrouwen 
werden in de jaren '60 geïntroduceerd. Sindsdien zijn deze preparaten op grote 
schaal toegepast om follikelgroei te stimuleren bij anovulatoire vrouwen. De 
ontwikkeling van de in vitro fertilisatie (IVF) techniek in de jaren '70 bracht een 
nieuw indicatiegebied voor het gebruik van gonadotrofinen met zich mee, 
namelijk de stimulatie van multipele follikels bij normocyclische vrouwen. 
Humaan menopauzaal gonadotrofine (hMG) is het oudste en meest frequent 
gebruikte gonadotrofinenpreparaat. Het bevat gelijke hoeveelheden follikel-
stimulerend hormoon (FSH) en luteïnizerend hormoon (LH). Humaan chorion 
gonadotrofine (hCG) wordt aan het preparaat toegvoegd en is verantwoordelijk 
voor een gedeelte van de LH-activiteit. 
In dit proefschrift beschreven we een aantal onderzoeken die uitgevoerd werden 
om onze kennis over gonadotrofinen te vergroten. Het effect van toediening van 
gonadotrofinen op hormonale parameters en op follikelgroei werd onderzocht in 
IVF-cycli, omdat in deze cycli eicel- en embryokwaliteit en de samenstelling van 
follikelvloeistof bestudeerd kunnen worden. De patiëntengroep bestond uit 
vrouwen met een normaal endocrien profiel, met tubapathologie of onbegrepen 
infertiliteit. Omdat de inclusiecriteria streng waren konden de onder-
zoeksgroepen relatief klein blijven, terwijl de cycli nauwkeurig geïnventariseerd 
werden. Zoals ook in deze studies, wordt toediening van gonadotrofinen in IVF-
cycli meestal gecombineerd met behandeling met een gonadotrofine releasing 
hormoon agonist (GnRHa), waardoor endogene gonadotrofinensecretie onder-
drukt wordt. 
Voorafgaand aan onze studies naar dagelijkse gonadotrofinentoediening in IVF-
cycli, onderzochten we het effect van eenmalige hMG-toediening, in combinatie 
met GnRHa (busereline) behandeling. HMG wordt routinematig toegediend via de 
intramusculaire (i.m.) route. Het verloop van serum FSH, LH en hCG con-
centraties na eenmalige i.m. injectie van 150 IU hMG (Humegon) werd beschre-
ven in hoofdstuk 2. Alternatieve toedieningsroutes zijn in de literatuur beschre-
ven, namelijk de pulsatiel intraveneuze (i.v.) en de subcutane (s.с.) route. Omdat 
we deze toedieningsroutes in onze IVF-studies wilden toepassen, hebben we 
ook het effect van eenmalige i.v. en eenmalige s.c. injectie van 150 IU hMG 
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onderzocht (hoofdstukken 2 en 3). FSH spiegels hadden vanzelfsprekend een 
ander verloop na i.v. dan na i.m. injectie, maar het verloop van de FSH con-
centraties na s.c. toediening vertoonde sterke gelijkenis met dat na i.m. injectie. 
Het gebruik van gevoelige en specifieke immunoassays maakte het mogelijk om 
LH en hCG ¡mmunoreactiviteit te onderscheiden. Exogene LH concentraties 
konden nauwelijks gemeten worden na toediening van 150 IU hMG, met name 
na i.m. en s.c. injectie, door de interferentie van endogeen LH. Daarom werd 
een andere studie uitgevoerd om farmacokinetische parameters van LH, hCG en 
ook van FSH te onderzoeken (hoofdstuk 4). Een GnRHa depotpreparaat (tripto-
reline) werd gebruikt om de endogene LH en FSH spiegels sterker te onder-
drukken dan met busereline neusspray. Een eenmalige dosis van 225 IU hMG 
(Humegon of Pergonal) werd i.v. toegediend. De halfwaardetijd van FSH 
bedroeg 22 uur, de halfwaardetijd van hCG ongeveer 15 uur. Exogeen LH kon 
inderdaad worden gemeten, maar verdween te snel om een betrouwbare 
schatting van de halfwaardetijd te maken. 
Vervolgens werd het effect van dagelijkse hMG toediening bestudeerd in IVF-
cycli. In alle cycli werd een vaste dagelijkse dosis van gonadotrofinen gegeven, 
omdat aanpassing van de dosis aan de individuele respons verschillen in effect 
zou kunnen maskeren. Het routine behandelschema werd bestudeerd in de 
studie die is beschreven in hoofdstuk 5. Dagelijks werden 150 IU hMG (Hume-
gon) i.m. toegediend, in combinatie met GnRHa (busereline) behandeling. Het 
effect op follikelgroei en op serum FSH, LH, hCG, 17ß-oestradiol en progesteron 
concentraties werd bestudeerd. De standaard behandeling werd vergeleken met 
pulsatiel intraveneuze toediening van hMG. In een eerdere niet-gerandomiseerde 
studie werd een toename in het zwangerschapspercentage beschreven na 
pulsatiel intraveneuze hMG toediening. In onze gerandomiseerde studie konden 
we geen verschil tussen de twee toedieningsroutes aantonen met betrekking tot 
follikelgroei, endocriene parameters en eicel- en embryokwaliteit. Omdat we 
geen aanwijzingen vonden voor een mogelijk gunstig effect van pulsatiel 
intraveneuze behandeling, besloten we om geen verdere studies met deze 
toedieningsroute uit te voeren. 
HMG bevat FSH en LH activiteit in een ratio van 1:1. De laatste tijd bestaat er 
een tendens om gonadotrofinenpreparaten met minder LH activiteit te gebruiken. 
Uit dierexperimenteel onderzoek bleek dat excessieve LH activiteit een on-
gunstige invloed had op follikelgroei. Aan de andere kant is een kleine hoeveel-
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heid LH noodzakelijk voor adequate ovariële stimulatie. We hebben twee studies 
uitgevoerd met gonadotrofinenpreparaten met verlaagde LH activiteit, en de 
effectiviteit van deze preparaten vergeleken. In hoofdstuk 6 beschreven we een 
gerandomiseerde studie waarin behandeling met Normegon, een hMG preparaat 
zonder toevoeging van hCG, met een FSH en LH activiteit in een ratio van 3 : 1 , 
werd vergeleken met Metrodin, een gezuiverd FSH preparaat met een FSH/LH 
ratio van > 6 0 : 1 . In beide groepen werd adequate ovariële stimulatie gezien, dus 
blijkbaar was de hoeveelheid LH voldoende voor follikelontwikkeling en voor 
steroidproduktie in de follikels. 
Metrodin, gezuiverd urinair FSH, heeft nog een minimale LH activiteit. Het recent 
ontwikkelde recombinant humaan FSH heeft volstrekt geen LH activiteit. Dit 
preparaat wordt geproduceerd door een genetisch gemanipuleerde Chinese-
hamster ovariumcellijn en blijkt vrijwel identiek te zijn aan urinair FSH. Het 
recombinant FSH preparaat heeft een grotere biochemische zuiverheid dan de 
urinaire preparaten. Waarschijnlijk zal recombinant FSH uiteindelijk de urinaire 
hMG en FSH preparaten vervangen. We hebben het effect van i.m. toediening 
van hMG (Humegon) en recombinant FSH (Puregon) in IVF-cycli vergeleken 
(hoofdstuk 7). In beide groepen werd multipele follikelontwikkeling met adequate 
serum steroidspiegels gezien. Blijkbaar was toediening van exogeen LH niet 
noodzakelijk voor ovariële stimulatie, zelfs tijdens suppressie van endogene LH 
spiegels door een GnRH agonist. De steroidsamenstelling van follikelvloeistof na 
behandeling met de diverse preparaten (Normegon, Metrodin, Humegon, 
Puregon) was niet significant verschillend (hoofdstukken 8 en 9). Dit bevestigt 
de waarneming dat, althans in onze onderzoeksgroep, de hoeveelheid exogeen 
LH niet essentieel was voor follikelgroei en steroidproduktie. 
Door de grote biochemische zuiverheid van recombinant FSH is subcutane 
toediening mogelijk. S.c. injecties verdienen de voorkeur boven i.m. injecties, 
omdat ze eenvoudiger zelf toe te dienen en wellicht minder pijnlijk zijn. We 
hebben de effectiviteit en de lokale tolerantie van i.m. en s.c. toediening van 
recombinant FSH vergeleken (hoofdstuk 7). Beide toedieningsroutes bleken 
effectief te zijn en goed verdragen te worden. 
In de diverse studies werden kleine verschillen in de resultaten van de onder-
zoeksgroepen gezien. Het aantal follikels en eicellen was iets lager na Metrodin 
dan na Normegon behandeling. Dit verschil zou verklaard kunnen worden door 
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de kleinere hoeveelheid LH in Metrodin. Wanneer i.m. recombinant FSH met 
hMG behandeling vergeleken werd, leek het aantal follikels en eicellen echter 
juist groter. Blijkbaar was dus de hoeveelheid LH niet de verklaring voor de 
waargenomen kleine verschillen. Een andere verklaring zou een verschil in 
isohormoonprofielen van de preparaten kunnen zijn. Meer basische isovormen 
van FSH blijken een andere in-vitro en in-vivo bioactiviteit en receptor affiniteit 
te bezitten dan meer zure isovormen. De verdeling van de isovormen kan bij de 
diverse gonadotrofinenpreparaten verschillend zijn, hetgeen verschillen in 
biologische activiteit kan verklaren. 
Concluderend hebben we meer inzicht gekregen in de kinetiek van gonadotro-
finen en hebben we beschreven dat de effectiviteit van gonadotrofinenbehan-
deling niet beïnvloed werd door de toedieningsroute. Gonadotrofinenpreparaten 
met een verlaagde hoeveelheid LH leidden toch tot adequate ovariële stimulatie 
bij vrouwen met een normaal endocrien profiel, zelfs tijdens hypofysaire sup-
pressie door een GnRH agonist. De resultaten van behandeling met een zuiver 
FSH preparaat, geproduceerd met behulp van recombinant DNA technieken, 
waren veelbelovend voor de toekomst van de infertiliteitsbehandeling. 
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Stellingen 
behorend bij het proefschrift "Gonadotrophins, some basic and clinical aspects". 
1 FSH spiegels in serum vertonen een vergelijkbaar profiel na intramus-
culaire en subcutane toediening van hMG {ditproefschrift). 
2 De toedieningsroute van de gonadotrofinenpreparaten (intramusculair, 
pulsatiel intraveneus of subcutaan) heeft weinig invloed op het resultaat 
van de ovariële hyperstimulatie (dit proefschrift). 
3 Toediening van exogeen LH is niet noodzakelijk voor ovariële hyperstimu-
latie bij normogonadotrope vrouwen (dit proefschrift). 
4 Bij normogonadotrope vrouwen worden vergelijkbare androgeen- en 
oestrogeenspiegels in follikelvloeistof gemeten na behandeling met recom-
binant FSH en hMG (ditproefschrift). 
5 Naast de endocrinologie gaat de paracrinologie een grote rol spelen. 
6 Toepassing van microchirurgische sperma aspiratie (MESA) bij mannen 
met congenitale ductus deferens agenesie zal leiden tot een toename van 
het aantal dragers van het cystic fibrosis-gen. 
7 "Why do we age?" may be the wrong question. The right question may 
be, "Why do we live as long as we do?" (Hayfiick, in: The underlying molecular, 
cellular, and immunological factors in cancer and aging. Yang SS, Warner HR, eds. Plenum 
Press, New York, 1993, ρ 38). 
8 Als de overheid zegt dat eerste lijn en thuiszorg moeten worden bevor­
derd en tegelijkertijd opleidingen en arbeidsplaatsen voor gezinszorg, wijk-
ziekenzorg en wijkverpleging inkrimpt, is er sprake van inconsequent 
beleid. 
9 Kouvatten bestaat niet. 
10 Art ¡s the result of expressing an emotion, thus it helps people to com-
municate with each Other (Anonymous, Museum of Natural History, Bulawayo). 
11 Het is in de wetenschap belangrijk om altijd in het achterhoofd te houden 
dat een zwarte doos rood kan zijn. 
12 Op de maatschappelijke ladder gelden nog steeds de regels van de 
etiquette: de vrouw komt na de man. 
Ingrid Duijkers 
Nijmegen, 8 november 1995 


